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From the screening of human liver cDNA library, we isolated a novel clone 
that has a high sequence identity (95%) to liver-specific transporter (NLT / 
hOAT2 / SLC22A7), and it is believed to be the human homolog of rat 0AT2 / 
NLT. The 1647-nucleotide long hOAT2 cDNA encodes a protein with a deduced 
molecular weight of 60 kDa. It is regarded as the second member of organic 
anion transporter (OAT) because of its characteristic twelve putative 
transmembrane domains and sequence similarity to OATl. H0AT2 possesses a 
large extracellular loop plus a possible A^-glycosylation site within the loop. 
It has been demonstrated that hOAT2 has a high level of expression in liver 
and relatively weak in kidney, while expression was only observed in liver when 
analyzed in fetal tissues, the mRNA transcript of hOAT2 was detected in cancer 
liver as well. Chromosomal localization of hOAT2 has been deduced to 
chromosome 6p21.2 - p21.1 by radiation hybrid mapping panel. Subcellular 
localization of hOAT2 using green fluorescence technique showed apparently to 
I localize in cytosolic area of HepG2 and C2C12 cells. Anti-hOAT2 antibodies 
1. 
I 






我們從人類肝臟的C D N A文庫可以分離到新的克隆，它的序列跟BT臟 
有關的載體9 5 % 相 同 （ N L T / h 〇 A T 2 / S L C 2 2 A 7 ) ， 相 信 跟 
人類同族體。長1 6 4 7 個核甘酸的 h O A T 2 的 c D N A編成蛋白質的分 
子量.推斷爲6 0 k D a °由於它有獨特的十二條穿透細胞區段和序列跟〇 





抄本中檢測到。從放射混合總畫技術h 0 A T 2在染色體上的位置被推斷爲 
在染色體6 P 2 1 . 2至0 2 1.1。而用綠色螢光技術表面顯示hOAT 2 
在H e p G 2和C 2 C 1 2的細胞質找到。利用反h 〇 A T 2抗體，發現H 




a.a. Amino acid 
b l a s t Basic Local Alignment Search Tool 
bp Base pair 
cMOAT Canalicular multispecific organic anion transporter 
EDTA Ethylenediaminetetracetic acid 
E S T S Expressed sequence tags 
IPTG Isopropylthio-b-D-galactoside 
MOPS (3-[N-Morpholino]propanesulfonic acid) 
NCBI National Center for Biotechnology Information 
NLT Novel liver-specific transporter 
Ntcp Na+-dependent taurocholate cotransporting polypeptide 
OAT Organic anion transporter 
OAT-Kl Kidney-specific oatp 
Oatp Organic anion transporter polypeptide 
PGR Polymerase chain reaction 
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SDS Sodium dodecyl sulfate 
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Chapter 1: Introduction 
1.1 Human EST sequencing project, the role and goal 
The rapid growth of international bioinformatics development and the 
combination with high throughput sequencing systems, a number of genetic 
sequences have been decoded in an exponential speed in the recent years. In 
1995, the first bacterial genomic sequences have been announced (Fleischmann 
et al., 1995). Yeast, worm and fly genomes have also been sequenced 
consecutively in 1996, 1998 and 1999 respectively. On June 26, 2000, the first 
draft sequence of the human genome has been completed, this announcement 
was made by the International Human Genome Project Consortium and Celera 
Genomics. Clearly, cracking the genetic code is a breakthrough to the scientific 
community, and certainly that such sequencing tasks are believed to take years to 
fully analyze. 
Expressed sequence tags (ESTs) sequencing project is playing an another 
role, in addition to genomic sequence, in revealing the mystery of human genetic 
code. Large-scale partial sequencing of cDNA libraries to generate ESTs is 
widely utilized, which discovers novel genes and characterizing transcription 
profiles in various tissues, including the brain, the liver and lymphocytes (Adams 
1 
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et al., 1991; Adams et cd., 1992; Adams et al., 1993a; Adams et aL, 1993b; 
Okubo et aL, 1992). 
Data from single-pass sequencing of cDNA clones has also been used in 
other applications such as the construction of physical maps of chromosomes 
(Khan et al； 1992; Wilcox et al., 1991). Primers are designed according to the 
information from EST sequences, which are then used to define sequence-tagged 
sites (STSs) in the genome. STS is a short and operationally unique in the 
genome, which is used to generate mapping reagent after amplification with PGR 
(Olson et al, 1989). 
1.2 Human liver cDNA sequencing 
Comparing with the western countries, it is not hard to observe that the 
incident rate of liver diseases such as cirrhosis, cholestasis and hepatitis is quite 
significant in Hong Kong. Statistical report 97/98 from Hospital Authority also 
figured out liver occupied the second high incident rate of leading cause of 
cancer in male (Figure 1.1). In our EST sequencing project, it mainly consists of 
!： three different sources of human liver cDNA libraries, normal liver from a 
r [. 
( 
Caucasian male, normal liver from a Chinese male and hepatitis induced cancer 
i 
I: 
I: liver from an Chinese male. We target to analyze and differentiate the gene 
i: 
；； 2 
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expression patterns among the libraries, and to elucidate cancer induced and 
novel genes that are ubiquitously expressed and that may therefore be important 
in the general maintenance of cell function. In addition, we would like to develop 
EST sequence database that contains the information specific to hepatocellular 
system from Chinese people. 
Figure 1.1 Incident rate of five leading causes of cancer in male from 1990 to 
1994 
Mala 
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1.3 The role of membrane-associated proteins in hepatocellular 
functions 
1.3.1 Outline of the liver function 
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various synthetic, metabolic functions and the detoxification of many 
endogenous and exogenous compounds such as excess amino acids, cholesterol, 
steroid hormones, bilirubin, toxins and many drugs (Frimmer and Ziegler, 1988; 
Meier, 1991). In other cases, it takes up various nutrients from the afferent blood, 
then it converts and stores them in carbohydrates, proteins and lipids. Upon nerve 
impulse or hormonal stimuli, these substrates wi l l be released into the circulation. 
Whereas the movement of these substrates or ions in and out to a cell or 
organelle must pass through the basic structure, cell membrane. 
1.3.2 Basic structure of hepatocyte 
In the liver hepatocyte membrane structures, they include the nucleus, 
mitochondrion, peroxisome, endoplasmic reticulum, Golgi apparatus, lysosome, 
endosome, plasma membrane, and various types of vesicles. While the plasma 
membrane in the highly polarized hepatocyte is further differentiated into three 
separate membrane domains: apical domain, lateral domain and basal (sinusoidal) 
domain. The apical domain is a small microvillous area, which constitutes bile 
canaliculi and is involved in the secretion of bile salts into the bile. The lateral 
domain is a smooth surface bearing several types of junctions, mainly takes part 
B 
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circulation, which is participated in the secretion of serum proteins, uptake of 
molecules and communication with the biological system through its receptor 
that bind growth factors, hormones, and other biologically important ligands 
(Handler, 1989; Rodriguez-Boulan and Nelson, 1989). The distinct properties of 
these domains including transporting activities show the essential role playing by 
membrane proteins in which the proteins components largely confer the 
specificity of the membrane. 
1.3.3 Category of membrane associated proteins 
The distribution of human liver ESTs listed by functional categories is 
shown in the table 1.1. ESTs that are matched with known genes are classified 
into mainly eleven categories according to their apparent functions. It is noted 
that this large EST database is constructed by our cooperative works of our 
colleagues in our laboratory through the processes of cDNA sequencing, post-
sequence editing, data analyzing, computer processing and other maintenance 
tasks. The proportions of membrane-associated proteins only accommodate a low 
percentage but roughly similar among the cDNA libraries for normal (3.5%), 
. normal-tumor (3.6%) and tumor (2.0%) tissues. 
I; 
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Table 1.1 Frequency distribution of human liver true normal, tumor-normal 
and tumor ESTs classified by functional categories. 
Category Normal lib Tumor- Tumor lib 
normal lib 
Frequency Frequency Frequency 
(%) (%) (%) 
Contractile clement 2 (0.4) 6 (0.2) 8 (0.2) 
Cytoskeletal related 6 (1.1) 35 (1.2) 60 (1.4) 
Extracellular matrix 0 (0.0) 11 (0.4) 34 (0.8) 
Energy metabolism 14 (2.5) 116 (3.9) 254 (6.1) 
Hormone and hormonal control 7 (1.2) 33 (1.1) 35 (0.8) 
Signal transduction/cell cycle 17 (3.0) 80 (2.7) 201 (4.8) 
regulation 
Transcription and translation 21 (3.7) 473 (15.9) 1264 (30.3) 
Membrane associated 19 (3.3) 108 (3.6) 83 (2.0) 
Secretory protein 335 (58.5) 1281 (43.1) 764 (18.3) 
Other metabolism 93 (16.3) 437 (14.7) 857 (20.6) 
Miscellaneous 58 (10.2) 393 (13.2) 613 (14.7) 
Subtotal 570 (100) 2973 (100) 4173 (100) 
Novel 147 804 1218 
Mitochondrial related 83 845 673 
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1.4 Identification of human OAT2 gene 
For over 800 cDNA partial sequences from human liver EST project, about 
one-fifth of them were identified as novel category. The first notification of 
0AT2 gene was found in the novel gene category. A cDNA clone called aa402, 
which is closely matched (84% nucleotide identity) with Rattus norvegicus liver-
specific transport protein (NLT) (Simonson et al., 1994). 
The first isolation of rat organic anion transporter 1 (OATl) was performed 
by Sekine et al. (1997). Physiological and pharmacological studies and sequence 
alignment between OATl and NLT, revealed that they are similar in both 
multispecificity, characteristic tissue distribution and sequence identity (Sekine et 
al, 1998). To this point, NLT was supposed to be a member of the OAT family 
and be renamed as 0AT2. 
Kim, RB et al (Unpublished) submitted the human liver-specific transporter 
(NLT) mRNA sequence to the GenBank database in 1999. Although its 
molecular function or transportation property is not yet characterized, the high 
nucleotide sequence similarity between rat 0AT2 and human NLT made us to 
speculate that human NLT is the human homolog of rat 0AT2. 
For standardizing purpose, the human 0AT2 gene was sent to HUGO Gene 
Nomenclature Committee (HGNC) for assigning a formal gene name. Solute 
: 7 
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carrier family 22 member 7 (SLC22A7) was denoted as alternative name for 
hOAT2. 
1.5 The multispeciflc transporter family 
1.5.1 Classification 
When lipophilic xenobiotics are transported into hepatocytes and extensively 
biotransformed by P450- and transferase-mediated reactions. The produced 
negatively charged amphiphilic compounds must be secreted from the 
hepatocytes. As a result, multispecific transporters of anionic compounds are 
necessary for the liver (Meier et aL, 1995; Petzinger E et al., 1994). 
i Up t i l l now, at least three multispecific transporter families were identified, 
I 
I 
they are ATP-binding cassette (ABC) superfamily, organic anion transporting 
i polypeptide (oatp) superfamily and organic anion transporter (OAT) superfamily. 
i 
, The ATP-binding cassette (ABC) superfamily includes P-glycoprotein, a 
r 
‘ multidrug resistance associated protein and a canalicular multispecific organic 
I 
anion transporter (cMOAT) which is considered to mediate hepatobiliary 
I . • 
> excretion of organic anions. Na+-independent oatp, prostaglandin transporter and 
kidney-specific oatp (OAT-Kl) are belongs to oatp superfamily. The OAT 
superfamily was newly discovered when the distinct structural and transport 
I « 
i 
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characteristics of OATl had been identified (Sekine et al., 1997). To date, four 
members of OAT include OATl, 0AT2, OATS and 0AT4 have been sequenced 
and characterized. 
1.5.2 The human OAT family 
The striking feature of this organic anion transport system is its wide 
substrate selectivity, covering not only endogenous substrates and also a number 
of important therapeutic drugs (Cihlar et al., 1999). Are there any associations 
among these transporters, in molecular basis or physiological reaction? Is there 
any common binding domain for recognizing organic anions? Studies on 
structurally related isoforms could facilitate our understanding on their 
multispecific properties. 
hOATl is found to strongly express in kidney and weakly in brain 
(Hosoyamada, 1999). Numerous organic anions including endogenous 
compounds, xenobiotics and their metabolites are eliminated by kidney, which 
are extracted though the basolateral membrane. Physiological studies show it 
mediates probenicid- and alpha-ketogultarate-sensitive /?ara-aminohippurate 
(PAH) transport when expressed in Xenopus Laevis oocytes (Race et al., 1999). 
Another two, possibly a result of alternatively spliced sequences of hOATl, the 
9 
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hOATl-1 and hOATl-2, were isolated by Hosoyamada et al. (1999). Whereas the 
difference between hOATl-2 and hOATl-1 is the 13-amino acid deletion located 
near the carboxyl terminal on hOATl-2. In addition to the mediation of PAH 
transport by hOATl-1, it was also demonstrated that hOATl-1 is inorganic 
anions dependent and the replacement of extracellular CI" with other anions or 
mannitol suppressed the PAH uptake (Hosoyamada et al., 1999). This 
phenomenon has been reported other than Xenopus Laevis oocytes expression 
system such as sliced rabbit kidney (Goldinger et al., 1980), basolateral 
membrane vesicles from bovine kidney (Schmitt and Burckhardt, 1993) and 
basolateral membrane vesicles from rat kidneys (Inui et al., 1986). 
hOAT3 shows 46% amino acid sequence identity to hOATl. Chromosomal 
mapping found that both of the hOATl and hOAT3 genes were localized to 
chromosome 11. Northern blot analysis demonstrated they were highly expressed 
in kidney (Race et al., 1999). The apparent similarities do not confer related 
functional properties in the oocytes expression experiments. Organic anions such 
as PAH, urate and TEA that were found to be increased uptake by hOATl did not 
appear to be the substrates of hOAT3. 
The human 0AT4 was the latest member among the OAT family, which was 
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Although the crystalline structures of the four transport proteins have not yet 
been elucidated, they share a common feature of twelve-putative transmembrane 
domains. The multispecific property was also elucidated in hOAT4. It mediated 
the transport of estrone sulfate, dehydroepiandrosterone sulfate (DHEA-s) and 
orcharatoxin A, where DHEA-s is a precursor of estrogen. The choice of these 
substrates was in consideration of the tissue specificity of hOAT4 protein and 
high expressions were detected in placenta and kidney (Cha et al., 2000). 
Whereas the uptake of DHEA-s by the placenta is important in synthesizing 
estrogens (estrone, estradiol, and estriol), and also keep the fetus away from the 
cytotoxicity of DHEA-s (Cha et al., 2000). 
1.6 The characteristics of rat multispecific OAT2 
To date, the functional or molecular studies on the human 0AT2 protein 
have not yet been clearly defined. One could provide some clues as to the 
understanding of hOAT2 is its rat homolog, rOAT2 (NLT). R0AT2 gene had 
been sequenced by Simonson et al. (1994). It encodes a 535 amino acid protein 
that possesses twelve putative transmembrane regions. A preferential expression 
of rOAT2 was detected in liver and rather weak in kidney by Northern blot 
analysis (Sekine et al., 1998). Indirect immunostaining of rat liver section was 
11 
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used to investigate the rOAT2 location in hepatocyte. Monoclonal antibody 2C5, 
which was specific to the transporter, detected the highest signal on the 
sinusoidal domain, rather than the lateral and the canalicular regions. 
Furthermore, the expression of the rat 0AT2 is developmentally regulated. In 
liver development, it showed a very low level in 19-21 gestation period to nearly 
a 5-fold increase in post-partum stage (Simonson et al., 1994). 
Considerations on the functional characterization of rOAT2 protein were 
based on two main categories, the organic anions multispecificity and the liver-
specific properties. A group of organic anions including a-ketoglutarate, 
prostaglandin E�，acetylsalicylate, PAH and therapeutic drug, methrotrexate were 
sorted in the uptake experiments using the oocytes expression system (Sekine et 
a l , 1998). R0AT2 had been demonstrated significant mediation of these anions, 
except for the low-level uptake of PAH was detected. It was one of the evident to 
show the similar structure of rOATl to rOAT2 did not represent having similar 
transport efficacy, where a much higher level of PAH transport was detected in 
rOATl (Sekine et al., 1997). Table 1.2 summarizes the various characteristics of 
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Table 1.2 Molecular and functional characteristics of organic anion 
transporters in this study. 
Designation Species Amino Tissue Substrate Accession Reference 
acids distribution 
OATl Rit 551 Kidney PAH, glutarate AB004559 (Sekine et 
al., 1997) 
OAT2 (NLT) Rat 535 Liver, Salicylate, a- L27651 (Simonson 
Kidney ketoglutarate, PGE2 et al., 1994) 
0AT3 Rat 536 Liver, PAH, ochratoxin A, ABO 17446 (Kusuhara 
Kidney, estrone sulpfate, etal, 1999) 
Brain cimetidine 
OATl-1 Human 563 Kidney PAH AB009697 (Hosoyama 
da et al, 
1999) 
SLC22A6, Human 550 Kidney PAH AF1243 73 (Cihlar et 
(OATl ), al., 1999; 
hOATl-2 Hosoyamad 
a et al., 
1999; Race 
etal., 1999) 
SLC22A7 Human 548 Liver, Unknown AF097518 This study, 
(OAT2) Kidney (Kim et al, 
unpublishe 
d) 
OATS Human 568 Kidney Unknown AF097491 (Race et al, 
1999) , 
0AT4 Human 550 Kidney, Estrone sulfate, AB026116 (Cha et al. 
Placenta DHEA-s, ochratoxin 2000) 
A, PAH 
PAH, ； 7 - a m i n o h i p p u r a t e ; PGE2, prostaglandin E�； DHEA-s, 
dehydroepiandrosterone sulfate; NLT, novel liver-specific transporter. 
13 
j 
Chapter 1: Introduction 
1.7 Clinical significance of organic anion transport proteins 
Cholestasis is one of the focuses in studying hepatic membrane transporters. 
Either the impairment of bile secretion from the hepatocyes into the canaliculi or 
the obstruction to the flow of preformed bile through the biliary tract wi l l 
possibly leading to this disease. Bile acid secretion from sinusoidal blood into 
bile is mediated by several kinds of transport proteins locating in the sinusoidal 
(basolateral) hepatocye membrane. 
Na^-taurocholate cotransporting polypeptide (Ntcp) is one of the involved 
transporters responsible for bile acid uptake in a sodium-dependent manner 
(Hagenbuch and Meier, 1994; Hagenbuch et al., 1991). Based upon experimental 
i 
i studies on rats, Ntcp showed a downregulation of taurocholate uptake in 
I 1 j 
I cholestasis such as bile duct ligation (Gartung et al., 1996) and endotoxinemia 
•I j 




S in human cholestatic liver with primary biliary cirrhosis. A significant inverse 
I 
J 




plasma bilirubin concentration indicated downregulation of Ntcp was also found 
in man (Shneider et al., 1997). Such inhibitory regulation of bile acid uptake 
i probably serves to protect the hepatocyte from further intracellular accumulation 
I of potentially toxic bile salts in case of the canalicular efflux systems for bile 
i \ 
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acids are impaired (Bossard et al., 1993). 
In addition to Ntcp, members of sodium-independent organic anion 
transporting polypeptides (Oatp), Oatpl and Oatp2, were also found to be down-
regulated in ethinyl estradiol cholestasis (Simon et aL, 1996) and during liver 
regeneration (Gerloff et al., 1999). Such differential regulation of these 
basolateral organic anions transporters in regenerating liver might protect 
replicating liver cells by diminishing uptake of potentially hepatotoxic bile salts, 
because the remaining liver initially cannot cope with the original bile acid pool 
size (Gerloff er a l , 1999) 
Numerous drugs and endogenous compounds are excreted via a transport 
system, organic anion transporters such as OATl and OATS were seemed to be 
related in mediating nephrotoxicants like (3-lactam antibiotics, mycotoxins and 
sevoflurane degradation product (compound A) (Endou, 1998). For example, 
mycotoxins such as ochratoxin A (OTA), which was clarified as a rate-limiting 
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2.1 Human liver EST sequencing project 
2,1,1 Plating out the adult human liver phage library 
A single colony of Escherichia coli bacterial host (XL 1-Blue MRF') was 
inoculated in 50ml of LB broth supplemented with 0.2% (w/v) maltose and lOmM 
Mg2S04, with shaking at 30°C in 250rpm overnight. The cells were centrifuged at 
2,000rpm (Beckman rotor JLA-16.250) at 4。C for lOmin and the cell pellet was 
resuspended in 15ml of lOmM MgaSO*. 
100 to 150 pfu of the X-ZAV phage of adult human liver cDNA library 
(Clontech) was added to 200|il of host cells in lOmM Mg2S04. The phage bacteria 
mixture was then incubated at 37。C for 15min. Concomitantly, 2ml of NZY top 
agar prewarmed to 48。C with 15|al of 0.5M IPTG and lOjul of X-gal (50mg/ml) 
were prepared. The incubated mixture plus the top agar solution were then plated 
onto prewarmed at (37。C) NZY plates and allowed to set for lOmin, and then the 
plates are incubated at 37°C overnight. 
The semi-transparent plaques were picked and transferred to 50|il of 
suspension medium buffer (lOOmM NaCl, 9mM Mg2S04 50mM Tris-HCl, 0.01% 
gelatin) which allowed the phage to diffuse. The phage stocks were ready for PGR 
16 
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and stored at 4。C. 
2.1.2 PCR detection and amplification of the cDNA clone 
PGR was performed using forward and reverse primers of 入-ZAP (5'-
CCAAGC TCGAAA TTAACC CTC -3 ' ) and M13 Universal primer (5'-
CGACGT TGTAAA ACGACG GCCAGT -3 ' ) respectively. The 50|al reaction 
mixture included 2\A phage suspension, 2.5mM each of the forward and reverse 
primers, 5[i\ lOX reaction buffer (Pharmacia), 0.5|LI1 Tag polymerase ( 2 . 5 U / | L I 1 , 
Pharmacia), and 5\i[ 2mM dNTP (Pharmacia). The reaction started by 30 cycles of 
denaturing at 95。C for 30sec, followed by 50。C for 35sec and 72°C for 2 min. The 
final extension proceeded at 72° for 5min using a programmable thermal cycler 
PTC-100 (MJ Research, Inc.). 
After the cycling reactions were completed, the PCR products were analyzed 
on a 1% TBE (O.IM Tris-HCl, 0.08M boric acid, ImM EDTA) agarose gel for 
checking insert sizes and purity. In order to obtain an efficient sequencing 
productivity, this step is crucial to isolate vectors that have very small inserts, no 
insert or disability to be amplified. The PCR product that produced a single 
obvious band under the electrophoresis was chosen for further DNA sequencing. 
17 
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2,1.3 Automatic cDNA sequencing 
Approximate 150ng of PGR product was used as template, with additional to 
2\A lOX sequencing buffer, l U Thermosequenase DNA polymerase and 5pmol 
fluorescein conjugated CY5-T3 sequencing primer (5'-GCTCGA AATTAA 
CCCTCA CTAAAG -3，) to work as a master mix. They were then added 
separately into 4^1 termination mix dATP/ddATP, dTTP/ddTTP, dCTP/ddCTP and 
dGTP/ddGTP. A drop of mineral oil was added on the surface of the liquid layer to 
prevent vaporization during the reaction. The sequencing reaction was started at 
94°C for 35sec, 50°C for 35sec and 72°C for Imin 30sec. 30 cycles were repeated 
and a final extension at 72°C for lOmin. Afterwards, Sjul of stop solution (95% 
formamide, 20mM EDTA and lOmg/ml blue dextran) was mixed to terminate the 
reaction. 
The reaction mixtures individually terminated with the four 
dideoxynucleotides ddATP, ddTTP, ddCTP and ddGTP were electrophoresed on a 
6% polyacrylamide gel by using automated DNA sequencer (ALF automated 
sequencer, Pharmacia™) for 6 hours. 
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2.2 Cloning of hOAT2 gene into TA cloning vector pT-Adv 
2.2.1 Amplification ofhOATl by PCR 
One 1^1 of cDNA from human fetal liver (Invitrogen) was used as templates for 
a total of 50|al PCR mixture. Forward (5'- ATGGGC TTTGAG GAGCTG 
CTGGA) and reverse primers (5'- TTAGTT CTGGAC CTGCTT CATGGG) 
which flank the two ends ofhOAT2 gene with 0.2mM dNTPs, I X PCR buffer and 
l U DNA polymerase mix from Clontech Advantage® cDNA polymerase kit were 
added to commence the reaction. PCR was performed according to the following 
protocol: 94°C for 30 s; 36 cycles of 94°C for 30 s, 60°C for 45 s and 68°C for 2 
min; 68°C for 5 min. The reaction conditions were manipulated by PTC-200 
thermal cycler (MJ Research Inc.). 
2.2.2 Ligation reaction 
A 10|Lil volume of ligation mixture composed of approximately 25ng of 
freshly prepared PCR product, 1|li1 of lOX ligation buffer (Clontech), 2|al of 
25ng/|Lil pT-Adv vector (Appendix), l|al T4 DNA ligase (4.0 Weiss units/|Lil, 
Clontech) and sterile water. Finally, it was taken to incubation at 16°C overnight. 
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2,2,3 Transformation of recombinant plasmid into competent cells 
Before transformation, one 50-|il of frozen TOPI OF' E.coli competent cells 
(Clontech) were thawed on ice. 2\i\ of ligation product along with 2\x\. of p-
mercaptoethanol were pipetted into the tube and incubated on ice for 30min. Then 
it was heat shocked in the 42°C water bath for 30sec and immediately transferred 
into ice for 2 min. The cells were recovered by adding 250|LI1 of SOC medium, 
shaked at 225rpm at 37°C for Ihr. lO^il o fX-Gal (50mg/ml) and IPTG (400mM) 
with lOOfil transformation mixture were spreaded on LB plate containing 50|Lig/ml 
of either kanamycin or ampicillin at 37°C overnight. Colonies in white were ready 
to pick for further analysis. 
2.3 Sequence analysis and structural prediction 
The BLAST is a set of similarity program (Altschul et al., 1994) containing 
large nucleotide and peptide sequences database which provides a fast and updated 
sequence similarity search. The ESTs and other genetic sequences similarity 
searches were determined by BLAST, National Center for Biotechnology 
Information, Bethesda, Maryland (NCBI) (http://www.ncbi.nlm.nih.gov/BT.AST). 
Amino acid and nucleotide sequence alignments were performed using BLAST 2 
sequences (NCBI) for pair alignments (Tatusova and Madden, 1999), ClustalW 
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(freely downloaded from 
http://www. sgi.com/chembio/resources/clustalw/parallel_clustalw.html) and 
DNASIS for multiple alignments. Prediction of transmembrane regions and 
orientation in protein sequences was done by DNASIS and HMMTOR While the 
transmembrane helices and topology for transmembrane proteins were analyzed 
using Hidden Markov Model (Tusnady and Simon, 1998). The presence of motifs 
in the amino acid sequence hOATl was predicted using PROSITE scan from 
Network Protein Sequence Analysis (NPS@) at Pole Bio-Informatique Lyonnais 
(PBIL), France (http://pbil.ibcp.fr/NPSA/npsa_proscan.html). 
2.4 Cloning of the hOAT2 gene into the pQE30 expression vector 
2.4.1 PCR amplification and restriction endonuclease cutting 
Restriction cutting sites BamYil and Sail were designed on the forward and 
reverse primers respectively to amplify the hOAT2 gene: 
Forward: 5'-TAGGGC GGATCC GGCTTT GAGGAG CTGCTG GAGCAG 
Reverse: 5'- TAGGGC GTCGAC TTAGTT CTGGAC CTGCTT CATGGG 
-3', whereas end-clamps consist of TAGGGC flanking the 5' region of both 
primers were aimed to facilitate the restriction enzymes digestion 
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PGR was performed according to the following conditions: 94°C for 30 s; 36 
cycles of 94。C for 30 s, 60。C for 45 s and 72。C for 2 min; 72。C for 5 min. 
Restriction cutting of the PGR product was prepared in a total volume of 20|^1 
composed of 2X One-Phor-All PLUS buffer (Pharmacia), 0.5^1 of each restriction 
enzymes, BamHl and Sail, and approximately 1 [ig of PGR product. Then the 
reaction was carried out at 37°C for three hours as well as the restriction digestion 
was done for the expression vector pQE30 (Appendix) by those enzymes in the 
same conditions. 
2.4,2 Gene clean 
The restriction digested PGR product and vector were purified by using 
GENECLEAN™ II I kit (Bio 101 Inc.) in order to remove excess salt and the 
unwanted digested fragments. The DNA was electrophoresed on a 1% TAE 
agarose gel for about 20min in constant voltage of 120V. The desired band was 
excised from the gel and placed in 3 volumes of 6M sodium iodide. It was then 
incubated in55°C water bath for lOmin until the gel was completely solublized. 10 
to 15 \x\ of GLASSMILK which depends on the DNA amount was mixed and 
incubated at room temperature for 15 min with occasional shaking. They were 
centrifuged at 15,000 x g for 30 sec. The supernatant was discarded, and the pellet 
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was washed with 500|LI1 of ice-cold NEW WASH solution three times. The pellet 
was dried by speed vacuum before the same volume of sterile water to 
GLASSMILK was added to resuspend the pellet and eluted the bound DNA. 
Afterwards, the DNA extracted after centrifugation was collected and 
subsequently quantified by running on a 1% TBE agarose gel. 
2.4,3 Preparation of bacterial competent cells 
A single bacterial colony of Escherichia coli M15(pREP4) was inoculated 
with 2ml LBK (25|^g/ml kanamycin) medium at 37°C overnight with shaking at 
250rpm. 250|li1 of the overnight culture was inoculated into 25ml LB medium 
containing the appropriate antibiotics which was then incubated at 37°C for about 3 
hours with shaking at 250rpm until it reached log phase. The culture was collected in 
a 50 ml centrifuge tube. 
The bacterial cells were spun down by centrifuging at 3,000rpm (Beckman 
rotor JLA-16.250) for 15 min at 4。C. The pellet was resuspended in one-third volume 
of original culture of RFl buffer (lOOmM RbCl, 50mM MnClaWHsO, 30mM 
potassium acetate, lOmM CaCl2.2H20, 15% w/v glycerol, pH 5.8). The bacterial 
cells were incubated on ice for 15 to 20 min before centrifuging at 3,000 rpm 
(Beckman rotor JLA-16.250) at 4°C for 15 min. The pellet was then resuspended in 
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1/12.5 volume of the original culture of RF2 buffer ( lOmM MOPS, lOmM RbCl, 
75mM CaCl2-2H20, 15% w/v glycerol, pH 6.8). The bacterial cells were chilled on 
ice for another 15 to 20 min. Thereafter, they were aliquoted into 200jul fractions 
contained by pre-chilled microcentrifuge tubes for later use. The competent 
bacterial cells were frozen in liquid nitrogen and stored at -70°C. 
2.5 Small scale synthesis of plasmid DNA 
The mini-preparation of plasmid DNA was performed by using Promega 
Wizard® plus SV Minipreps DNA Purification System. After transforming the 
recombinant plasmid DNA in appropriate E.coli strain and plated out, a single 
colony was picked and inoculated in a 2ml culture and incubated at 37°C with 
shaking overnight. The cell culture was then poured into a 1.5ml microcentrifuge 
tube and centrifuged at 10,000 x g for 5 min. After the supernatant was removed, 
250|al of Cell Resuspension Solution was added with vortexing. Afterwards, 250jLil 
of Cell Lysis solution, 10|li1 of Alkaline Protease Solution and SSOjul of 
Neutralization Solution were mixed accordingly by inverting the tube and 
incubated not longer than 5 minutes between each solution was added. The 
bacterial lysate was centrifuged at 14,000 x g for lOmin, the supernatant was 
transferred to a Minipreps Spin Column. Under centrifUgation at 14,000 x g for a 
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minute, plasmid DNA trapped in the column was further washed with Column 
Wash Solution and at last the DNA was eluted with 60^1 of sterile water. 
2.6 Large scale synthesis of the plasmid DNA 
A single colony was picked from master plate and inoculated in a starter 2ml 
culture for 8 hours at 37°C, 250 rpm. 10ml of log phase culture was diluted in 
100ml selective medium for another growth at 37°C for overnight, 250rpm. 
The cells were centrifuged at 6,000 x g at 4°C for 15min and the pellet were 
resuspened in 10ml of buffer PI (100|ag/ml Rnase A, 50mM Tris-HCl, lOmM 
EDTA pH 8.0). Cells were lysed 10ml of buffer P2 (1% SDS, 200mM NaOH), and 
the tube was inverted several times and incubated for 5min at room temperature. 
Another 10ml of chilled buffer P3(20mM KOAc, pH 5.5) was mixed to the lysate, 
then the lysate were immediately poured into the QIAfilter Cartridge (QIAGEN) 
and filtered after 10 minutes incubation. 
Purification of plasmid DNA was achieved by running the filtered lysate into 
QIAGEN anion-exchange resin column which was pre-equilibrated by 10ml 
buffer QBT (750mM NaCl, 50mM MOPS, pH 7.0, 15% isopropanol). Majority of 
contaminants from the plasmid preparation were removed by washing the column 
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Afterwards, 15ml of buffer QF (1.2 M NaCl, 50mM MOPS, pH 8.5, 15% 
isopropanol) was added for elution. DNA collected was precipitated by 10.5ml 
isopropanol and centrifuged at 15,000 x g for 30min at 4°C. The pellet was washed 
with 5 ml 70% ethanol and further centrifuged at 15,000 x g for lOmin. Finally, the 
purified plasmid DNA was redissolved by adding on appropriate volume of sterile 
water. 
2.7 Cloning of the hOAT2 gene into the pSecTaglB mammalian expression 
vector 
In additional to the end clamp sequence TAGGGC, restriction sites BamHI in 
forward primers and JiTzo/site in reverse primers were placed in the hOAT2 cDNA 
by flanking its ends. 
Forward primer 5'- TAGGGC GGATCC GGGTTT GAGGAG CTGCTG 
GAGCAG -3' 
Reverse primer 5'- TAGGGC CTCGAG TGTTCT GGACCT GCTTCA 
TGGGCAT-3 ' 
The conditions used in the PGR amplification were described in cloning of 
pQE30 vector. After a series of processes such as restriction cutting, ligation and 
transformation into bacterial host for vector propagation, the transformants were 
plated onto LB A selective plates (100|Lig/ml). 
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2.8 Cloning of the hOAT2 gene into the pEGFP-Cl fluorescent vector 
Amplification of the hOAT2 inserts were performed using the forward primer 
(5'- AGGGCC TCGAGC TATGGG CTTTGA GGAGCT GCTGGA -3') and the 
reverse primer (5'- TAGGGC GGATCC TTAGTT CTGGAC CTGCTT CATGGG 
-3') which synthesized the transcripts flanking with two restriction sites Xhol and 
iSa//respectively. An end-clamp, TAGGGC, was added to the 5' end of the primers 
to enhance the restriction site cutting. The PGR was done according to the profile 
that was mentioned above with little modification of the annealing temperature to 
62。C for 45 s. 
After restriction enzymes cutting, they were cloned into the green fluorescent 
vector pEGFP-Cl. The transformants were plated onto LBK plates with 25|Lig/ml 
of kanamycin. 
2.8,1 Tissue culture and transfection 
C2C12 myoblasts, was maintained in RPMI-1640 medium or DMEM 
medium (Life Technologies, Inc.) supplemented with 10% (vol/vol) heat-
inactivated, certified Fetal Bovine Serum (Life Technologies Inc.), 1% antibiotics 
(penicillin, 100 units/ml; streptomycin sulfate, 100 |Lig/ml) at 37°C in 5% CO2 in a 
humidified atmosphere. Cells were subcultured every 2 days. 
The recombinant expression vectors carrying the insert hOAT2 were purified 
27 
Chapter 2: Materials and Methods 
as described in this chapter. C2C12 myoblasts was transfected with various 
plasmid constructs using Lipofectamine Plus Reagent (Life Technologies, Inc.). 
Approximate 1 x 10^  Cells were grown on coverslips in six-well plates, until the 
cells were 60-70% confluent. 1 jug of DNA and 4 |al of the Plus Reagent were 
added to 125 |i l RPMI-1640 medium lacking serum and antibiotics and incubated 
for 15 min at room temperature. 4 |LI1 of lipofectamine reagent were added to 125 
medium without serum and antibiotics to another new tube and incubated for 15 
min at room temperature. After incubation, these two solutions were mixed and 
incubated for another 15 min at room temperature. The cells were washed with 
PBS twice. 1 ml of serum free medium was added to the cells. The DNA-
lipofectamine plus mixture was added to the cells and incubated for 3 hours at 
37°C. After that, the cells were rinsed with PBS and fresh medium supplemented 
with 10% FBS and antibiotics was added followed by incubation for another 24 
hours before microscopic examination. 
2.8.2 Fluorescence microscopy examination 
For epi-fluorescence microscopy (Zeiss Axioskop fluorescence microscopy), 
cells expressing GFP fusion protein was viewed with either a GFP filter set 
(Omega Optical, Inc.). Images were captured by cooled CCD camera 
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(Photometeric, Inc) (exposure 1 to 4 s) and were artificially colored using IpLab 
spectrum software. 
2.9 Chromosomal mapping of the hOAT2 gene 
2.9.1 Somatic cell hybrids mapping 
Gene specific primers were designed from the coding sequence of the hOAT2 
gene (Forward: 5'- GGCTGG GAGTAC GACCAC TCAGAA T; Reverse: 5'-
AGGCCC AGCACC AGGGTA CTCAC). PCR was first performed to a 24 
somatic cell hybrids DNA panel (human / rodent somatic cell hybrids mapping 
panel 2-Version 3; National Institute of General Medicine Service Coriell Cell 
Repositories) (Drwinga et aL, 1993) using the Advantage polymerase kit 
(Clontech). The working conditions used were as follows: initial denaturation at 
94。C for 1 min; 32 cycles of 94。C for 30 s, 65。C for 30 s, 68。C for 1.5 min; and a 
final extension at 68°C for 5 min. The presence of gene specific bands was 
analyzed on 2% agarose / EtBr gel. 
2.9.2 Radiation hybrids mapping 
A higher fidelity map was applied by a PCR-based radiation hybrid mapping 
technique using the Genebridge 4 human / hamster whole-genome Radiation 
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Hybrid Panel RH02.05 (Gyapay et al., 1996). It includes 93 hybrid genomic 
DNAs from the same number of human-on-hamster somatic cell lines, and also 
two control genomic DNAs (HFL human, A23 hamster). Twenty-five ng of 
genomic DNA was used for the PGR using the same primers performed in somatic 
hybrids mapping. The final products were checked on 2% agarose gel. The 
resulting 1-kb PGR product was subcloned into the TA cloning vector (Clontech) 
and sequenced for confirmation. 
The scores of "1" and "0" were used to represent the presence and absence of 
specific bands respectively, while ambiguous bands were taken as “2” . Duplicate 
typings were performed before analysis. A string of scores generated from the 
screening results were processed by the software RHMAPPER at the Whitehead 
Institute / MIT Center for Genomic Research (Lee et al., 1998). 
2.10Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
The steps of mRNA preparation and the conversion from mRNA to cDNA by 
reverse transcriptase were avoided by using Multiple Tissue cDNA (MTC) Panels 
(Clontech). They are sets of normalized, first-strand cDNA generated using RNA 
from different human tissues. A set of PCRs were performed whereas the primers 
set and condition profile were optimized according to various MTC panels. 
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Forward primer F1 (5'- ATGGGC TTTGAG GAGCTG CTGGA) and reverse 
primer R2 (5'- ATCTCT TCCTCC TGAAGA CTGGTT) were chosen in human 
normal MTC panel. For human cancer and fetal MTC panels, forward primer F2 
(5'- GATCTG GTGTGT GAGCAG AAAGG) was utilized instead of F l . One-
fifth ng of each cDNA preparation was amplified in a total volume of 25\A. The 
same PGR profile was used in all panels of first denaturing at 94°C for 1 min; 35 
cycles of94°C for 30 s, 57。C for 45 s, 72°C for 2 min; and final extension at 72。C 
for 10 min. The PGR products were analyzed in 1% agarose gel. 
The relative abundance of specific transcripts within panels was normalized 
using a housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (G3PDH). 
lOjuM of G3PDH Control Primer Mix provided in the kit with upstream primer: 
5'- TGAAGG TCGGAG TCAACG GATTTG GT -3' and downstream primer: 5'-
CATGTG GGCCAT GAGGTC CACCAC -3, that amplify the G3PDH gene in a 
〜1-kb fragment. 
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2.11 Western hybridization 
2,11.1 Preparation of anti-hOAT2 antibodies 
2.11.1.1 Synthetic peptide conjugation 
A peptide sequence which is specific to human consisting 15 amino acids 
(NTTLGEERQSRGELE, postion 91-105) at the amino-terminus of human 0AT2 
was synthesized. 0.1 mg of the synthetic peptide was conjugated with keyhole 
limpet hemocyanin (KLH) solution (5mg/ml) for 30 min. NHS (5mg/ml) and 
ED AC (lOmg/ml) were added with stirring for 30 min. This conjugate was then 
purified with a G-25 Sephadex desalting column (Pharmacia) equilibrated with 
PBS. The cloudy eluent was aliquoted and stored at -20°C, and ready for injection. 
2.11.1.2 Immunizing rabbit polyclonal antibodies for human OAT2 
0.5ml of the KHL-hOAT2 peptide (100|Lig) was emulsified by mixing 0.5ml of 
Freund's complete adjuvent for the first subcutaneous injection into a rabbit. 
Incomplete Freund's adjuvent was used in the boosts six weeks after priming 
immunization. Ten to forteen days after the boost, the first blood was collected. 
Boost immunization and blood collection were continued in 4-week interval, the 
rabbit was killed at the fifth blood drawing. The blood was clotted at room 
temperatre before it was centrifuged at 5,000 x g at 4°C to remove blood clot and 
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cell debris. Finally the serum was stored at -20°C. 
2.11.1.3 Purification of the rabbit polyclonal IgG antibodies 
Purification of the rabbit anti-hOAT2 antibodies was done by running through 
a HiTrap protein G affinity column (Pharmacia). The column was prepared by 
removing the top-cap and a drop of start buffer (0.02 M sodium phosphate, pH 7) 
was applied to the top of the column to avoid air bubbles. The ethanol preservative 
was washed out from the column with 3 ml start buffer. The column was 
equilibrated with 3 bed volumes of start buffer. 2ml of serum separated from 
rabbit's blood was applied onto the column using a syringe. The column was 
washed with 5ml start buffer. Then, the column was eluted with 4ml elution buffer 
(O.IM glycine-HQ, pH 2.7) and collected in microcentrifuge tubes of each with 
1ml fraction. Each 100 |LI1 neutralizing buffer (l.OM Tris-HCl, pH 9.0) was added 
to each fraction to restore the pH around 7. The purified polyclonal IgG was 
aliquoted and stored at -20°C. 
2,11.2 Western blot analysis 
2.11.2.1 Protein isolation from rat liver 
Liver tissue resected from rat was homogenized in TRJZOL Reagent 
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(GibcoBRL) in the concentration of 75mg/ml. Three phases were separated after 
adding chloroform and followed by centrifugation. The lower red, phenol-
chloroform phase was aspirated, 0.3ml of 100% ethanol per 1ml of TRIZOL 
Reagent used for the initial homogenization was mixed. After sedimentation, the 
phenol-ethanol supernatant was isolated for protein preparation. 1.5ml of 
isopropanol per 1 ml of TRIZOL Reagent was added, the protein was centrifuged 
at 12,000 X g for lOmin at 4°C. The protein pellet was washed three times with 
washing solution (0.3M GuHCl in 95% ethanol) and centrifuged at 7,500 x g for 5 
min at each wash. The cleaned protein pellet was dissolved in 1% SDS solution 
and stored at -20°C. 
2.11.2.2 Protein preparation from cell lysate 
A 20mm flask containing about Ix 10^ cells were ready for protein collection. 
The medium in the culture flask was discareded and then the cells were washed 
with PBS three times. A scraper was used to detach the cells from the flask and a 
trace amount of PBS was used to resuspend the cells. The cells were moved to a 
1.5 ml eppendorf and centrifuged at 1,500 x g for 5 min. 50-100 |LI1 of lysis buffer 
mixed with protease inhibitor was added to resusupend the pellet, and incubated 
on ice for 15 min. Incubation in room temperature or higher is avoided to minimize 
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protein degradation. Finally, proteins were collected from the supernatant after 
further centrifugation at 10,000 x g for 10 min at 4。C. 
2.11.2.3 Quantitation of total proteins by Bradford protein assay 
Protein concentration was determined using Bio-Rad protein assay kit II. 
Protein standard was set up by diluting the standard Bovine Serum Albumin (BSA) 
solution into concentration of 0.9, 0.6, 0.3 and 0.2 mg/ml. The BioRad's 
Coomassie Reagent was five-fold diluted with deionized water while the protein 
samples were divided into 1/5, 1/10 and 1/20 dilutions. To each 20jLil of protein 
sample, 1ml of Coomassie Reagent was mixed and inverted 4 times. The sample 
mixture was allowed to incubate at room temperature for 5min for color 
development, absorbance at 595nm was taken thereafter. 
2.11.2.4 Blotting and hybridization 
Proteins from various sources were denatured by mixing loading buffer (2% 
SDS, 125mM Tris-HCL, pH 7.4, 20% glycerol, 2% p-mercaptoethanol) at 100°C 
for 5 minutes and electrophoresed on a 12% SDS-polyacrylamide gel thereafter. 
The gel was soaked in transfer buffer (25mM Tris, 192 mM glycine, 20% v/v 
methanol, pH 8.3) for 15 minutes before the proteins were transferred to 
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polyvinylidene difluoride (PVDF) membranes (Millipore) by Mini Trans-Blot 
electrophoretic transfer cell at 200V for 2 hours. 
The blots were blocked with 5% non-fat milk in Tris buffered saline (TBS)-T 
(20mM Tris, 137mM sodium chloride, I M hydrochloric acid, 0.05% Tween-20, 
pH 7.6) overnight at 4°C and incubated with the affinity-purified anti-hOAT2 
antibodies (1:300 dilution) for 1 h at room temperature. Goat anti-rabbit IgG 
conjugated with horseradish peroxidase (HRP, 1:3000 dilution, Amersham 
Pharmacia Biotech) secondary antibodies were used to incubate with the blots for 
another hour at room temperature. Enhanced chemiluminescence kit was applied 
for detection (Amersham Pharmacia Biotech), and the signal was exposed onto 
BioMax MR films (Kodak). For identification of the antibody specificity, the 
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3.1 Catalogue of the 500 liver ESTs 
The distribution of the 500 liver ESTs after homology search in BLAST was 
presented in the Table 3.1. Within the ESTs, 300 of them were generated from 
human normal liver cDNA library and the remaining 200 ESTs were generated 
from cancerous liver, as they were matched in according to their major functions. 
The overview of the gene expression pattern of these two libraries was 
summarized in the Table 3.2 below. 
Table 3.2 The overall pattern of gene expression in the 500 liver ESTs. 
Category Tumor liver Normal liver 
Frequency % Frequency % 
Matched genes 
Contractile element (CE/CO) 0 0.0% 0 0.0% 
Cytoskeletal related (CY) 4 3.0% 2 0.9% 
Extracellular matrix (EX) 1 0.7% 0 0.0% 
Energy metabolism (EN) 6 4.5% 4 1.8% 
Hormone and hormonal control 1 0.7% 2 0.9% 
(H) 
Signal transduction/cell cycle 10 7.5% 4 1.8% 
regulation (CS) 
Transcription and translation 42 31.3% 7 3.1% 
(TT) 
Membrane associated (M) 4 3.0% 5 2.2% 
Secretory protein (OS) 32 23.9% 146 65.2% 
Other metabolism (OM) 21 15.7% 37 16.5% 
Miscellaneous (Ml) 13 9.7% 17 7.6% 
Subtotal 134 100.0% 224 100.0% 
Overall 
Matched genes 134 75% 224 80% 
Novel 26 14% 24 8% 
Mitochondrial 20 11% 33 12% 
Total 180 100% 281 100% 
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Table 3.1 The human liver ESTs that were matched to known genes, either 
human or non-human matches, were classified into eleven categories. Each 
category as shown in the table includes the accession number, distribution 
frequency and P-value, a) The 281 EST sequences of P < 0.001 generated 
from 300 clones of normal adult liver cDNA library. 
Subject Accession^ P Value Class 
casein kinase 1 alpha (c) gi|1432066 e-114 CS 
cell cycle regulatory protein p95 (NBS1) gi|3098674 e-165 CS 
C0P9 complex subunit 7a (C0PS7a) (b) gi|3309173 5e-83 CS 
Gephyrin (a) gi|56311 e-111 CS 
myosin light chain kinase isoform 3B (MLCK) gi|4322023 e-166 CY 
tubulin, beta-, clone 24464 gi|3387979 e-159 CY 
electron transfer flavoprotein beta subunit gi|297901 0 EN 
glucokinase regulator giI683571 1e-35 EN 
isocitrate dehydrogenase, NADP-dependent (IDH) gi|3641397 e-140 EN 
succinate dehydrogenase flavoprotein subunit (SDH) gi|347133 e-100 EN 
angiogenin gi|178249 e-126 H 
angiotensinogen gi|178643 e-156 H 
gp96, human homologue of murine tumor rejection antigen gi|37260 e-111 M 
HLA-DMA (HLA-DMA34 allele) gi|450815 e-103 M 
low-affinity IgG Fc receptor (beta-Fc-gamma-RII) gi|184843 8e-87 M 
major histocompatibility complex (HLA-BM4031) gi|1929863 5e-69 M 
TGN46 protein gi|1518268 3e-83 M 
autonomously replicating sequence (ARS) gi|179295 0 Ml 
haptoglobin related (Hpr) gi|32446 1e-69 Ml 
haptoglobin related protein gi|1495457 e-109 Ml 
HIV-1 TAR RNA binding protein (TARBP-b) gi|347963 e-129 Ml 
KIAA0108 gi|285962 0 Ml 
KIAA0214 protein gi|3869186 0 Ml 
Ku (p70/p80) subunit gi|186793 7e-68 Ml 
metallothionein-IG (MT1G), (clone 14VS) gi|188712 5e-58 Ml 
mRNA clone with similarity to L-glycerol-3-phosphate:NAD gi|763428 0 Ml 
oxidoreductase and albumin gene sequences. 
polyA site DNA gi|505034 0 Ml 
polyA site DNA gi|505035 9e-75 Ml 
Proline synthetase associated gi|4126977 0 Ml 
RasGAP-related protein (IQGAP2) gi|1262925 7e-62 Ml 
SDP3 gi|3126978 2e-49 Ml 
selenoprotein P gi|36425 0 Ml 
unknown protein gi|393314 0 Ml 
unknown protein gi|393314 e-106 Ml 
isolate Afr7 cytochrome b (CYTB) gene, mitochondrial gene gi|3372408 0 MITO 
encoding mitochondrial protein 
isolate Afr7 cytochrome b (CYTB) gene, mitochondrial gene gi|3372378 e-123 MITO 
encoding mitochondrial protein 
isolate Afr7 cytochrome b (CYTB) gene, mitochondrial gene gi|3372376 0 MITO 
encoding mitochondrial protein 
mitochondrial DNA, complete genome gi|1262342 e-141 MITO 
mitochondrial DNA, complete genome gi|1262342 e-139 MITO 
mitochondrial DNA, complete genome gi|1262342 e-125 MITO 
mitochondrial DNA, complete sequence gi|644480 0 MITO 
mitochondrial DNA, complete sequence gi|644480 0 MITO 
mitochondrial genome gi|13003 e-172 MITO 
mitochondrial genome gi|13003 e-124 MITO 
mitochondrial genome gi|13003 e-148 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-119 MITO 
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mitochondrial genome (consensus sequence) gi|13000 5e-98 MITO 
mitochondrial genome (consensus sequence) gi|13000 1e-97 MITO 
mitochondrial genome (consensus sequence) gi|13000 0 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-132 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-162 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-138 MITO 
mitochondrial genome (consensus sequence^ gi|13000 0 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-132 MITO 
mitochondrial genome (consensus sequence) gi|13000 2e-74 MITO 
mitochondrion, complete genome gi|1944628 e-154 MITO 
mitochondrion, complete genome gij 1944628 4e-79 MITO 
mitochondrion, complete genome gi|1944628 e-129 MITO 
mitochondrion, complete genome gij 1944628 e-178 MITO 
mitochondrion, complete genome gij 1944628 0 MITO 
mitochondrion, complete genome gij 1944628 e-137 MITO 
mitochondrion, complete genome gi|1944628 e-151 MITO 
mitochondrion, complete genome gij 1944628 0 MITO 
mitochondrion, complete genome gij 1944628 2e-96 MITO 
mitochondrion, complete genome gi|1944628 1e-50 MITO 
NADH dehydrogenase subunit 2 (ND2) gene, mitochondrial gi|3287312 0 MITO 
gene encoding mitochondrial protein 
NADH dehydrogenase subunit 2 (ND2) gene, mitochondrial gi|3287320 0 MITO 
gene encoding mitochondrial protein 
Apolipoprotein H (beta-2-glycoprotein I) gi|28811 e-109 N 
BAG clone GS165I04 from 7q21 gi|2275190 2e-91 N 
BAG clone RG066D11 from 7q22 gi|2335066 8e-45 N 
BAG clone RG161K23 from 7q21 gi|1809224 0 N 
Chromosome 16 BAG clone CIT987SK-582J2 gi|3219333 2e-84 N 
Chromosome 16 BAG clone CIT987-SKA-113A6 〜complete gi|2815548 0 N 
genomic sequence 
Chromosome 16 BAG clone CIT987SK-A-259H10 gi|3337388 e-165 N 
Chromosome 16 BAG clone CIT987SK-A-259H10 gi|3337388 e-119 N 
Chromosome 16 BAG clone CIT987SK-A-923A4 gi|3219338 1e-67 N 
chromosome 16，cosmid clone 363E3 (LANL) gi|3097841 9e-31 N 
cosmid clone LUCA13 from 3p21.3 gi|2337875 e-106 N 
DNA sequence from clone 390013 on chromosome Xp11 gi|3204451 0 N 
DNA sequence from clone 425C14 on chromosome 6q22 gi|3281967 3e-90 N 
DNA sequence from clone 662N3 on chromosome Xp21.1 - gi|4455593 4e-13 N 
21.3. 
DNA sequence from cosmid 65019, BRCA2 gene region gi|1322149 0 N 
chromosome 13q12-13 contains dinucleotide repeat 
DNA sequence from PAC 408N23 on chromosome 22q13 gi|2582746 5e-60 N 
glycoprotein, alpha-1 acid gi|178256 0 N 
Human immunodeficiency virus type 1 isolate F6E envelope gi|733351 0 N 
glycoprotein (env) 
Xp22 BAG GSHB-184P14 (Genome Systems Human BAG gi|3273378 6e-70 N 
library) 
adenylate kinase 1 (AK1), nuclear gene encoding gi|4502010 e-147 OM 
mitochondrial protein 
alcohol dehydrogenase beta-1-subunit (ADH1-2 allele) gi|28415 e-157 OM 
aldehyde dehydrogenase 1 (ALDH1) gi|2183298 0 OM 
aldehyde reductase gij 178480 8e-97 OM 
aldolase B gi|28616 e-110 OM 
aldolase B gi|178352 e-143 OM 
aldolase B gi|28616 e-105 OM 
arginase, liver gi|178994 e-161 OM 
argininosuccinate synthetase gi|28871 e-110 OM 
C1 inhibitor gi|29536 0 OM 
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C1 inhibitor gi|29536 2e-87 OM 
carbamyl phosphate synthetase I 9丨丨3228247 e-127 OM 
carbamyl phosphate synthetase I (EC 6.3.4.16) gi|219552 4e-17 OM 
cysteine dioxygenase type 1 gi|467560 8e-83 OM 
cytochrome P-3-450 gi|30338 8e-66 OM 
cytochrome P-3-450 gi|181307 e-163 OM 
cytochrome P450 2E1 (CYP2E1) gi|4249652 0 OM 
cytochrome P-450j gi|181359 0 OM 
fatty acid binding protein, liver (FABP) gi|182355 e-159 OM 
ferritin L chain gi|182513 e-159 OM 
ferritin L chain gi|182513 e-147 OM 
ferritin L-chain gi|2230868 e-136 OM 
ferritin light subunit gi|182517 2e-65 OM 
flavin-containing monooxygenase form II (FM02) gi|188630 e-100 OM 
homogentisate 1,2-dioxygenase gi|1561615 e-164 OM 
l-FLICE isoform 5 gi|2827297 e-149 OM 
KDEL receptor, a presumptive gi|34030 0 OM 
lambda-crystallin (c) gij 164904 7e-48 OM 
lanosterol 14-demethylase cytochrome P450 (CYP51) gij 1698395 e-117 OM 
nifedipine oxidase gi|181373 0 OM 
oxidative 3 alpha hydroxysteroid dehydrogenase gi|2661210 5e-79 OM 
phosphoglucomutase 1 (PGM1) gi|189925 e-138 OM 
serin protease with IGF-binding motif gi|1513058 e-168 OM 
serine dehydratase gi|338029 e-121 OM 
serine-pyruvate aminotransferase gi|36581 e-109 OM 
tyrosine aminotransferase (TAT) (EC 2.6.1.5) gi|36712 0 OM 
uridine diphosphoglucose pyrophosphorylase gi|881393 e-106 OM 
acid glycoprotein, alpha-1 gi|178256 e-144 OS 
acid glycoprotein, alpha-1 gij 178256 0 OS 
acid glycoprotein, alphal- (orosomucoid) gj[24444 0 OS 
acid glycoprotein, alphal- (orosomucoid) gi|24444 e-118 OS 
acid glycoprotein, alphal - (orosomucoid) gi|24444 0 OS 
acid glycoprotein, alphal - (orosomucoid) gi|24444 6e-96 OS 
acid glycoprotein, alphal - (orosomucoid) gj[24444 e-102 OS 
albumin (ALB) gi|4502026 3e-54 OS 
albumin (ALB) gi|4502026 0 OS 
albumin (ALB) gi|4502026 0 OS 
albumin (ALB) gi|4502026 e-177 OS 
albumin (ALB) gi|4502026 0 OS 
albumin (ALB) gi|4502026 1e-77 OS 
albumin (ALB) gi|4502026 2e-81 OS 
albumin (ALB) gi|4502026 e-171 OS 
albumin (ALB) gi|4502026 0 OS 
albumin (ALB) gi丨4502026 0 OS 
albumin (ALB) gi|4502026 e-151 OS 
albumin (ALB) mRNA gi|4502026 e-121 OS 
albumin (ALB) mRNA gi|4502026 2e-96 OS 
alpha-1-microglobulin/bikunin precursor (AMBP) gi|4502066 e-134 OS 
antichymotrypsin, alpha 1-gene fragment gi|28331 e-121 OS 
antichymotrypsin, alphal- gi|439142 e-153 OS 
antichymotrypsin, alpha-1-, precursor gi|4165889 0 OS 
antithrombin III (AT3) gi|4502260 e-114 OS 
antitrypsin, alpha 1- gi|28965 e-179 OS 
antitrypsin, alpha 1- gi|28965 0 OS 
antitrypsin, alpha 1- gi|28965 e-103 OS 
antitrypsin, alpha-1- gi|177828 1e-07 OS 
antitrypsin, alpha-1- gi| 177828 e-159 OS 
antitrypsin, alpha-1- gi|28965 e-160 OS 
antitrypsin, alpha-1- gi|28965 1e-32 OS 
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antitrypsin, alpha-1- gi|28965 e-151 OS 
antitrypsin, alpha-1- gi|177828 e-165 OS 
antitrypsin, alpha-1- gi|28965 1e-94 OS 
antitrypsin, alpha-1- gi|177828 e-156 OS 
antitrypsin, alpha-1- gi|177828 0 OS 
antitrypsin, alpha-1- gi|177828 0 OS 
antitrypsin, alpha-1- (S variant) gi|177830 4e-88 OS 
antitrypsin, alpha-1- (S variant) gi|177830 e-155 OS 
antitrypsin, Z type alpha-1- gi|177835 2e-90 OS 
apolipoprotein B100 giI178789 e-168 OS 
apolipoprotein B-100 gi|178803 2e-80 OS 
apolipoprotein B-100 gi|178817 e-111 OS 
apolipoprotein C-m (apoC-m) gi|178828 e-154 OS 
apolipoprotein J gij 178854 0 OS 
carboxypeptidase B, prepro-plasma gij 189686 e-151 OS 
complement component 4B (C4B) gi|4502500 e-168 OS 
complement component C3 (C3) gi|1162925 0 OS 
complement component C3 (C3) gi|1162925 e-150 OS 
complement component C3 , alpha and beta subunits gi|179664 e-159 OS 
complement component C3, alpha and beta subunits gij 179664 e-106 OS 
complement component C3, alpha and beta subunits gi|179664 e-153 OS 
complement component C3, alpha and beta subunits gi|179664 e-100 OS 
complement component C3, alpha and beta subunits gi|179664 e-128 OS 
complement component C9 gi|29580 2e-87 OS 
complement component C9 gi|29580 e-127 OS 
complement cytolysis inhibitor (CLI) gi|180619 e-147 OS 
complement factor B gi|297568 e-146 OS 
complement factor B gi|297568 e-138 OS 
complement factor B gi|297568 e-148 OS 
complement factor H gi|31964 0 OS 
C-reactive protein gi|181067 5e-97 OS 
C-reactive protein gi|30223 e-162 OS 
C-reactive protein gi|30212 2e-99 OS 
fibrinogen A-alpha-chain gij 182425 0 OS 
fibrinogen A-alpha-chain gi|182425 e-153 OS 
fibrinogen alpha chain gi|458553 e-134 OS 
fibrinogen alpha chain gi|458553 e-162 OS 
fibrinogen alpha subunit and fibrinogen alpha subunit gi|182406 7e-38 OS 
precursor 
fibrinogen alpha subunit and fibrinogen alpha subunit gi|182406 e-109 OS 
precursor 
fibrinogen alpha subunit and fibrinogen alpha subunit gi|182406 0 OS 
precursor 
fibrinogen alpha-chain gi|182423 2e-59 OS 
fibrinogen beta-chain gi| 182429 0 OS 
fibrinogen beta-chain gi|182429 e-178 OS 
fibrinogen beta-chain gi|182429 e-175 OS 
fibrinogen beta-chain gi|182429 e-143 OS 
fibrinogen beta-chain gij 182429 0 OS 
fibrinogen beta-chain gi|182429 2e-69 OS 
fibrinogen beta-chain gi|182429 4e-79 OS 
fibrinogen, A alpha polypeptide (FGA) gil4503688 e-101 OS 
fibrinogen, gamma gi|182441 8e-84 OS 
fibrinogen, gamma polypeptide (FGG) gi|4503714 6e-78 OS 
fibrinogen, gamma polypeptide (FGG) gi|4503714 e-159 OS 
fibrinogen, gamma polypeptide (FGG) gi|4503714 0 OS 
fibrinogen, gamma polypeptide (FGG) gi|4503714 0 OS 
fibrinogen, gamma polypeptide (FGG) gi|4503714 e-171 OS 
fibrinogen, gamma polypeptide (FGG) mRNA gi|4503714 e-164 OS 
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group-specific component (GC) gi|31675 e-162 OS 
haptoglobin alpha 1S (Hpa 1S) gi|32429 e-156 OS 
haptoglobin alpha 1S(Hpa1S) gi|32429 0 OS 
haptoglobin alpha 1S (Hpa 1S) gi|32429 e-162 OS 
haptoglobin alpha 1S (Hpa 1S) gi|32429 e-116 OS 
haptoglobin alpha 1S(Hpa1S) gi|32429 0 OS 
haptoglobin alpha 1S(Hpa1S) gi|32429 0 OS 
haptoglobin alpha 1S (Hpa 1S) gi|32429 0 OS 
haptoglobin alpha- and beta-chain gi|32417 1e-06 OS 
haptoglobin alpha- and beta-chain gi|32417 e-172 OS 
haptoglobin alpha(1S)-beta precursor gi|184316 e-144 OS 
haptoglobin alpha(1S)-beta precursor gi|184316 e-140 OS 
haptoglobin alpha(1S)-beta precursor giI184316 0 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-104 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-153 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-147 OS 
haptoglobin alpha(2FS)-beta gi|459812 0 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-164 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-102 OS 
haptoglobin alpha(2FS)-beta gi|459812 e-129 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 e-140 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 e-115 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 e-171 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 0 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 0 OS 
haptoglobin alpha(2FS)-beta precursor gi|31749 0 OS 
haptoglobin and haptoglobin-related protein (HP and HPR) gi|292156 e-140 OS 
haptoglobin gene (alpha-2 allele) gij 184327 0 OS 
hemopexin gi|184487 e-129 OS 
histidine-rich glycoprotein gi|184391 0 OS 
inter-alpha-trypsin inhibitor family heavy chain-related gi|664887 e-122 OS 
protein (IHRP) 
inter-alpha-trypsin inhibitor subunit 3 gi|32605 e-111 OS 
lipopolysaccharide binding protein (LBP) gi|2653815 e-104 OS 
microglobulin, alpha-1- (protein HC) gi|32046 e-169 OS 
microglobulin, alpha-1-and HI-30 gi|24478 e-178 OS 
plasminogen gi|190112 e-179 OS 
retinol binding protein (RBP) gi|35896 e-111 OS 
retinol binding protein (RBP) gi|35896 e-117 OS 
serum albumin gi|28591 e-138 OS 
serum albumin (HSA) gi|28589 0 OS 
serum albumin (HSA) gi|28589 0 OS 
serum albumin (HSA) gi|28589 e-162 OS 
serum albumin (HSA) gi|28589 7e-87 OS 
serum amyloid A (SAA) gi|337747 e-166 OS 
serum amyloid A (SAA) gij 1160968 e-119 OS 
serum amyloid A (SAA) gi|1160968 e-112 OS 
serum amyloid A (SAA) mRNA. gi|337747 e-158 OS 
serum amyloid A (SAA) protein partial, clone pAS3-alpha gi|36313 e-105 OS 
serum amyloid A1 (SAA1) gi|758678 e-120 OS 
serum amyloid A1 (SAA1) gi|758678 e-162 OS 
serum amyloid A1 (SAA1) gi|758678 0 OS 
serum amyloid P component (SAP) gi|36330 e-167 OS 
serum vitamin D-binding protein (hDBP) gi|181481 7e-71 OS 
thyroid hormone binding protein (p55) gi|339646 e-147 OS 
transferrin gi|248647 e-168 OS 
transferrin [human, liver, mRNA, 2347 nt] gi|248647 e-172 OS 
vascular cell adhesion molecule 1 gi|340193 1e-97 OS 
zinc alpha-2-glycoprotein 1 (AZGP1) gi|4502336 4e-82 OS 
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DNA topoisomerase II (partial) gi|288564 0 TT 
heterogeneous nuclear ribonudeoprotein complex K gi|241477 0 TT 
LPS-lnduced TNF-Alpha Factor (LITAF) gi|1684871 e-156 TT 
nucleolin (C23) (h) gi|191026 7e-98 TT 
polyadenylate binding protein II gi|693936 0 TT 
ribosomal protein L3 gi|313658 e-158 TT 
transcription factor CA150, putative gi|2460123 e-160 TT 
b) The 180 EST sequences of P < 0.001 generated from 200 clones of human 
adult liver tumor cDNA library. 
Subject Accession# P Value Class 
80K-L protein gi|219893 e-140 CS 
ADP-ribosylation factor 1，clone 24537 gi|3360490 e-172 CS 
annexin IV (carbohydrate-binding protein p33/41) gi|1060889 e-101 CS 
annexin IV (carbohydrate-binding protein p33/41) gij 1060889 0 CS 
calreticulin (CALR) gi|179881 4e-54 CS 
nm23-H2 gi|35069 e-121 CS 
ornithine decarboxylase (ODC) gij 189372 e-133 CS 
small G protein RIBB gi|2286100 e-171 CS 
thymosin beta-4 gi|339688 e-101 CS 
tyrosine kinase, non-receptor protein gi|37503 e-139 CS 
dynein light chain 1’ cytoplasmic (hdld) gi|1209060 6e-97 CY 
keratin 18 gi| 186690 1e-66 CY 
profilin II gi|190387 e-111 CY 
tubulin, beta- gi|338694 e-169 CY 
cytochrome c oxidase subunit VIb (EC 1.9.3.1) gi|30294 e-138 EN 
cytochrome oxidase subunit VIb gi|311347 e-160 EN 
electron transfer flavoprotein beta subunit gi|297901 e-150 EN 
enolase, non-neuronal gi|31176 1e-97 EN 
NADH:ubiquinone oxidoreductase B15 subunit gi|4164445 e-152 EN 
ubiquinol-cytochrome c reductase, smallest subunit of gi|2317645 e-150 EN 
tissue inhibitor of metalloproteinase-S precursor (TIMP-3) gi|472309 e-141 EX 
EBI3-associated protein p60 gij 1145798 e-163 H 
adipophilin gi| 1806039 e-134 M 
murine tumor rejection antigen gp96, tra1 mRNA for human gi|37260 2e-92 M 
homologue of 
signal sequence receptor, beta- gi|1019367 e-108 M 
tetraspan transmembrane protein L6H, putative (TM4SF5) gi|2587053 e-159 M 
CI-MNLL homolog gene gi|3342003 e-118 Ml 
D10S102=FBRNP gi|399757 e-102 Ml 
dek gi|30502 e-175 Ml 
fragile X mental retardation protein 1 homolog FXR1 gi|887792 e-169 Ml 
H19gene gi|3789930 e-148 Ml 
heat shock 10kD protein 1 (chaperonin 10) (HSPE1) gi|469170 e-126 Ml 
hypothetical protein, clone YR-29 gi|3881975 e-100 Ml 
immunoglobin light chain, (lambda) DNA for gi|2114261 5e-23 Ml 
KIAA0103 gi|285942 e-147 Ml 
non-histone chromosomal protein (HMG-1) gi|184250 3e-80 Ml 
retropseudogene. 
nucleolar protein p40 gi|1835785 e-159 Ml 
ubiquitin A-52 residue ribosomal protein fusion product 1 gi|37564 4e-76 Ml 
(UBA52) 
xs99 gi|533965 e-119 Ml 
cytochrome oxidase subunit II (COII), Hsa6 mitochondrion gi|530076 0 MITO 
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Isolate Aus4 cytochrome b (CYTB) gene, mitochondrial gene gi|3372411 e-174 MITO 
encoding mitochondrial protein, partial cds 
mitochondrial DNA gi|644480 1e-78 MITO 
mitochondrial DNA, complete genome gij 1262342 e-168 MITO 
mitochondrial DNA, complete genome gij 1262342 e-169 MITO 
mitochondrial DNA, complete genome gij 1262342 e-132 MITO 
mitochondrial DNA, complete genome gij 1262342 e-135 MITO 
mitochondrial DNA, complete genome gij 1262342 9e-99 MITO 
mitochondrial DNA, complete genome gij 1262342 0 MITO 
mitochondrial DNA, complete genome gij 1262342 e-153 MITO 
mitochondrial DNA, complete sequence gi|644480 2e-61 MITO 
mitochondrial genes for several tRNAs (Phe, Val, Leu) and gi|13683 5e-60 MITO 
12S and 16S ribosomal RNAs 
mitochondrial genes for tRNA (Phe) and 12S rRNA gi|12998 e-112 MITO 
(fragment) 
mitochondrial genes for tRNA (Phe) and 12S rRNA gi|12998 e-104 MITO 
(fragment) 
mitochondrial genome gi|13003 2e-97 MITO 
mitochondrial genome gi|13003 e-155 MITO 
mitochondrial genome (consensus sequence) gi|13000 5e-78 MITO 
mitochondrial genome (consensus sequence) gi|13000 e-148 MITO 
mitochondrion, complete genome gij 1944628 e-158 MITO 
NADH dehydrogenase subunit 2 (ND2) gene, mitochondrial gi|3287315 e-165 MITO 
gene encoding mitochondrial protein 
novel gi|458031 5e-05 N 
Novel gi| 1272369 1e-06 N 
novel (12q24.2 PAC RPCI1-128M12) gi|3366553 4e-71 N 
novel (BAG clone GS180J05 from 7q11) gi|2388557 2e-37 N 
novel (BAG clone RG313E03 from 7q31) gi|2828785 e-159 N 
novel 时 K region clone 2f10-rpi) gi|460086 6e-85 N 
novel (chromosome 21 derived BAG containing gi|2736086 e-164 N 
erythroblastosis virus oncogene homolog 2 protein (ets-2) 
gene) 
novel (Chromosome 22q11.2 PAC Clone p_n5 In BCRL2- gi|3900814 9e-23 N 
GGT Region) 
novel (chromosome 5, BAG clone 259m9 (LBNL H193)) gi|3540154 e-138 N 
novel (clone 23884) gi|3005703 9e-80 N 
novel (done 24560 unknown) gi|3005718 e-154 N 
novel (clone 24896) gi|4406688 e-128 N 
novel (clone 24955) giI4406629 e-136 N 
novel (clone 557 OTK27) gi|3859989 e-177 N 
novel (clone lambda MEN1 region unknown protein) gi|2529720 1e-89 N 
novel (DNA from cosmid MMDA from chromosome 19q13.3) giil88616 7e-78 N 
novel (DNA sequence from BAG 445C9 on chromosome gi|2661905 5e-66 N 
22q12.1) 
novel (DNA sequence from clone 88L2 on chromosome 1) gi|4140364 3e-24 N 
novel (DNA sequence from clone E146D10 on chromosome gi|3402828 e-103 N 
22) 
novel (DNA sequence from PAC 148E22 on chromosome gi|2791551 e-103 N 
20q12-q13.12) 
novel (DNA sequence from PAC 368A4 on chromosome X) gi|2578095 e-150 N 
novel (DNA sequence from PAC 368A4 on chromosome X) gi|2578095 e-105 N 
novel (Genomic sequence from Human 9q34) gi|2133911 e-165 N 
novel (Genomic sequence from Human 9q34) gi|2133894 3e-64 N 
novel iPAC clone DJ0777023 from 7p14-p15) gi|3242763 4e-62 N 
novel iPAC clone DJ0808A01 from 7q21.1-q31.1) gi|3694662 e-134 N 
26S proteasome ATPase subunit gi|2791679 e-176 OM 
aldehyde dehydrogenase 1 (ALDH1) gi|2183298 e-168 OM 
aldolase B gi|178352 4e-88 OM 
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Subject Accession# P Value Class 
ferritin H chain gi|28434 e-150 OM 
ferritin L chain gi|2230868 2e-62 OM 
ferritin L chain gi|2230868 e-131 OM 
ferritin L chain gi|182513 e-141 OM 
ferritin L chain gi|2230868 e-135 OM 
ferritin L chain gi|182513 e-161 OM 
ferritin L chain gi|28518 e-134 OM 
monoamine oxidase A (MAOA) gi|187352 3e-80 OM 
monocyte/macrophage serine-esterase 1, partial gi|36421 0 OM 
mutant cerebroside sulfate activator protein (SAP-MU-0) gi|337764 e-124 OM 
mRNA, complete cds, without the 9 bp insertion found 
inalternatively spliced mRNA. 
Na+/H+ exchange regulatory co-factor (NHERF) gi|2920584 e-117 OM 
NADPH-flavin reductase gi|1384067 e-168 OM 
natural killer cell enhancing factor (NKEFB) gi|440307 e-137 OM 
NDUFV3 gene gi|2230875 6e-63 OM 
proteasome subunit HsN3 gi|565650 2e-97 OM 
proteasome subunit z gi|1531532 e-128 OM 
sorbitol dehydrogenase (SORD) gi|2228516 e-152 OM 
ubiquitin gi|1490418 e-170 OM 
antitrypsin, alpha 1- gi|28965 4e-95 OS 
antitrypsin, alpha-1- gi|177828 e-154 OS 
apolipoprotein All gi|28743 e-142 OS 
apolipoprotein A-丨丨 giil78423 e-138 OS 
apolipoprotein A-II (AP0A2) gi|4502148 e-161 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 e-102 OS 
apolipoprotein A-II (AP0A2) gi|4502148 e-155 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 e-122 OS 
apolipoprotein A-II (AP0A2) gi|4502148 2e-37 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 e-168 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 e-137 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 0 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 1e-67 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 0 OS 
apolipoprotein A-ll (AP0A2) gi|4502148 e-141 OS 
apolipoprotein Cll gi|28799 e-113 OS 
apolipoprotein Cll gi|28799 2e-90 OS 
apolipoprotein Cll gi|28805 e-169 OS 
apolipoprotein C-ll (AP0C2) gi|4502158 5e-63 OS 
apolipoprotein C-lll (apoC-lll) gi|178828 e-177 OS 
haptoglobin Hp-alpha-2 gi|184322 e-101 OS 
microglobulin, alpha-1- (protein HC) giI32046 0 OS 
microglobulin, alpha-1- (protein HC) gi|32046 e-174 OS 
plasminogen gi|190112 0 OS 
prealbumin gi|189583 e-137 OS 
prealbumin gi|189581 0 OS 
retinol binding protein (RBP) gi|35896 7e-38 OS 
serum albumin gi|28591 e-152 OS 
serum albumin (ALB) gi|4502026 e-152 OS 
serum albumin (ALB) gij 178343 2e-69 OS 
serum albumin (ALB) gi|4502026 0 OS 
thyroid hormone binding protein (p55) gi|339646 0 OS 
acidic ribosomal phosphoprotein PO gi|190231 e-126 TT 
acidic ribosomal phosphoprotein P1 gi|190233 e-156 TT 
DNA-binding protein, insulinoma rig-analog mRNA encoding gi|184553 1e-82 TT 
H3.3A variant histone (b) gil1022324 e-144 TT 
nuclear factor NF45 gi|532312 2e-93 TT 
ribosomal protein L10 gi|414586 e-129 TT 
ribosomal protein UO gi|414586 e-150 TT 
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Subject Accession# P Value Class 
ribosomal protein L18 (RPL18) gi|337492 e-128 TT 
Ribosomal protein L18a gi|401844 e-152 TT 
ribosomal protein L18a gi|401844 0 TT 
ribosomal protein L23 gi|34198 e-110 TT 
ribosomal protein L23a gi|1399085 e-129 TT 
ribosomal protein L27 (RPL27) gi|388768 e-175 TT 
ribosomal protein L27a gi|550016 e-110 TT 
ribosomal protein L28 gi|550018 3e-70 TT 
ribosomal protein L32 gi|36131 3e-98 TT 
ribosomal protein L35 gi|562073 3e-73 TT 
ribosomal protein L37 gij 1839333 7e-84 TT 
ribosomal protein L37a gi|292438 4e-79 TT 
ribosomal protein L7 gi|36139 e-107 TT 
ribosomal protein L8 gi|433898 0 TT 
ribosomal protein L8 gi|433898 e-128 TT 
ribosomal protein S16 gi|338446 e-116 TT 
ribosomal protein S18 gi|38422 e-104 TT 
Ribosomal protein S19 gi|337732 2e-53 TT 
ribosomal protein S19 gi|337732 e-172 TT 
ribosomal protein S19 gi|337732 e-130 TT 
ribosomal protein S20 (RPS20) gi|292442 e-118 TT 
ribosomal protein S20 (RPS20) gi|292442 e-134 TT 
ribosomal protein S20 iRPS20i gi|292442 e-121 TT 
ribosomal protein S20 (RPS20) gi|292442 0 TT 
ribosomal protein S20 細S 2 0 i gi|292442 e-103 TT 
ribosomal protein S21 (RPS21) gi|292444 e-106 TT 
Ribosomal protein S21 (RPS21) gi|292444 e-138 TT 
ribosomal protein S27 gi|431318 2e-96 TT 
ribosomal protein S27 gi|1373420 e-167 TT 
ribosomal protein S28 gi|388030 e-166 TT 
ribosomal protein s3,40S gi|32531 e-144 TT 
ribosomal RNA, 16S gi|2245558 e-113 TT 
translation elongation factor 1-alpha (EF1A) gi|31091 e-128 TT 
translation elongation factor-1-beta gi|31099 e-160 TT 
TRAP-complex gamma subunit (a) gi|312701 5e-21 TT 
Key: 
(a) Rattus norvegicus (b) Mus musculus (c) Oryctolagus cuniculus (d) 
Arabidopsis thaliana (e) Caenorhabditis elegans (f) Nicotiana tabacum (g) 
Drosophila melangaster (h) Chinese hamster (I) Oryza sativa ( j ) Ipomoea 
batatas (k) Anabaena sp. 
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3.2 Nomenclature of human NLT gene 
The investigation of organic transporters has been started since the last 
decade. To date, there are at least two multispecific organic transporter families 
that have been identified, while the discovery of organic anion transporters are 
the latest finding in these few years. In order to prevent confusion or mix up with 
other anion transporters such as organic anion transporter polypeptide (oatp) or 
canalicular multispecific organic anion transporter (cMOAT), a formal and 
systemic name is necessary for the gene. 
The name NLT that stands for novel liver-specific transporter was first 
assigned when a novel rat liver-specific transporter was being identified 
(Simonson et al., 1994). In additional to the NLT amino acid sequence that 
exhibits 42% identity to that of OATl , it was also further demonstrated that it has 
multispecific organic anion transport properties by Sekine et al (1998) and a 
name called 0AT2 was being proposed. Until 1999, K im et al. proposed the 
corresponding provisional human sequence, which showed 78% amino acid 
identity. In order to have a centralized numbering system to distinguish the 
individual members of a human gene family, a new gene symbol was necessarily 
designated，in consideration of its structure, function and expression data. Having 
approved and suggested by the HUGO Gene Nomenclature Committee (HGNC), 
47 
Chapter 3: Results 
a formal gene name was denoted by our group to NLT or 0AT2 as the Solute 
Carrier Family 22 member 7 (SLC22A7). 
Up t i l l now, the name 0AT2 is commonly described in published papers. 
Together with the other three members hOATl, hOAT3 and hOAT4, they are all 
belong to a new subset of multispecific organic anion transporter family other 
than ABC and OATP family, or known as amphiphilic solute facilitator (ASF) 
family (Race et al., 1999). 
3.3 Cloning and characterization of the hOAT2 sequence 
3.3.1 Isolation of hOAT2 cDNA from human liver cDNA library 
From the large pool of human normal liver EST sequences generated 
previously in our laboratory, a partial cDNA clone named aa402 (483 bp) as one 
of the novel genes was identified. The sequencing pattern is shown in figure 3.2. 
Under the non-redundant BLAST search from NCBI, two reported sequences 
were shown apparently to match closely to the clone. They are the human liver-
specific transporter (NLT) (Accession: AF097518) from Kim et al. (1999, 
unpublished), and the rat liver-specific transporter (Accession: L27651) from 
Simonson et al. (1994) with nucleotide identities up to 95 % and 88% 
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liver-specific transporter has already been found, further sequence properties and 
protein functions associated with the gene have not yet been characterized. 
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Figure 3.1 The nucleotide sequence alignment of the clone aa402 was found 
to match with high identity with human and rat NLT under the BLAST search. 
Color Key for fHignnent Scor«s 
m B l — M E B B — m-m B — — — 
0 100 200 300 棚 
Human NLT mmmmm 
• — i • — — 
S c o r e E 
S e q u e n c e s p r o d u c i n g s i g n i f i c a n t a l i g n m e n t s : (bits) V a l u e 
g b l A F 0 9 7 5 1 8 . 1 I A F 0 9 7 5 1 8 H o m o s a p i e n s l i v e r - s p e c i f i c t r a n s p o r . . • 662 0 . 0 
g b I L 2 7 6 5 1 . 1 | R A T L S T P R a t t u s n o r v e g i c u s l i v e r - s p e c i f i c t r a n s p . . . 1 5 9 l e - 3 6 
g b I L 3 0 1 0 7 . 1 1 R A T L I V T R R a t t u s n o r v e g i c u s l i v e r - s p e c i f i c t r a n s … 1 0 1 2 e - 1 9 
g b | A F 0 1 3 7 5 4 . 1 I A F 0 1 3 7 5 4 G a l l u s g a l l u s t r a n s c r i p t i o n f a c t o r R … 4 2 0 . 2 0 
g b | L 4 8 4 7 7 . 1 I H U M 2 1 D C 9 3 Z H o m o s a p i e n s ( s u b c l o n e 6 _ b l 0 f r o m P I . . . 40 0 . 7 8 
einb|AL031231.11 S C 3 C 3 S t r e p t o m y c e s c o e l i c o l o r c o s m i d 3 C 3 40 0 . 7 8 
e m b I A L 0 4 9 8 2 9 . 4 | C N S O O O O B H u m a n c h r o m o s o m e 14 D N A s e q u e n c e ** … 38 3 . 1 
einb|AL021707.2 I H S 5 0 8 I 1 5 H u m a n D N A s e q u e n c e f r o m c l o n e R P 3 - 5 … 38 3 . 1 
g b I U 0 5 9 5 8 . 1 1 S A N K C C l S q u a l u s a c a n t h i a s b u m e t a n i d e - s e n s i t i v e . . . 38 3 . 1 
e m b 1X13768.11 S S P 4 5 S C P o r c i n e m R N A f o r c y t o c h r o m e P - 4 5 0 ( S C C … 38 3 . 1 
e m b I Z 9 6 6 0 1 . 1 | H S 3 Q T 0 1 3 H • s a p i e n s t e l o m e r i c D N A s e q u e n c e , c l o … 38 3 . 1 
e m b I X 7 5 9 5 6 . 1 | B T T G N P F M R B . t a u r u s m R N A f o r t r a n s g o l g i n e t w o r . . . 38 3 . 1 
A l i g n m e n t s 
> g b | A F 0 9 7 5 1 8 . 1 1 A F 0 9 7 5 1 8 H o m o s a p i e n s l i v e r — s p e c i f i c t r a n s p o r t e r (NLT) m R N A , 
c o m p l e t e c d s 
L e n g t h = 2 1 3 6 
S c o r e = 662 b i t s ( 3 3 4 ) , E x p e c t = 0 . 0 
I d e n t i t i e s = 4 3 6 / 4 5 7 ( 9 5 % ) , G a p s = 1 6 / 4 5 7 (3%) 
S t r a n d = P l u s / P l u s 
Query: 8 ggcacgctcagctcctgcctccgctttgcctatccccaggcgctctccaacaccacgttg 67 
> 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 m 11 I I I m I m 11 I I I I I I I 11 1 1 1 i i 1 1 1 1 1 i i i i i i i 
Sbjct: 318 ggcacgctcagctcctgcctccgctttgcctatccccaggctctccccaacaccacgttg 377 
Query: 68 ggggaagaaaggcagagccgtgtgtagctggaggatgaacctgccacagtgccctgctct 127 
1 1 1 1 1 1 1 1 1 m m 1 1 1 1 1 1 1 I 1 1 1 1 丨丨丨 11 丨 I 丨 m 11 丨 1 1 1 1 m 1 1 1 丨 I I I I I 丨 
Sbjct: 378 ggggaagaaaggcagagccgtggggagctggaggatgaacctgccacagtgccctgctct 437 
Query: 128 cagggctgggagtacgaccactcagaattcttctctaccattgcaactg agtgg 181 
I I I I I I I I I I I M I I M I I I I I I I M I I I M I I I I I m I I I I I I I I I I I I I I 
Sbjct: 438 cagggctgggagtacgaccactcagaattctcctctaccattgcaactgagtcccagtgg 4 97 
Query: 182 gatctggtgtgtgagcagaaaggtctgaacagagctgcgtccactttcttcttcgccggt 241 
： M I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I M M I I I M I I I I I M I I I 
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Query: 242 gtgctggtgggggctgtgg-ctttggatatctgt-cgaca-gtttgggcggcggcgtctg 298 
M I I M M M U L I I I M I I I M M M M M I I M M I I I M M I I I I I I I I I I I I 
Sbjct: 558 gtgctggtgggggctgtggcctttggatatctgtccgacaggtttgggcggcggcgtctg 617 
Query: 299 ctgctggtagcctacgtgagtaccctggtgctgggcctggcatctgcagcctccgt-agc 357 
I I I I M I I I I I I I I I I I I I I I I M I I I I I I M M M I I I I I I I I I I I I I I M I I I I I I I 
Sbjct: 618 ctgctggtagcctacgtgagtaccctggtgctgggcctggcatctgcagcctccgtcagc 677 
Query: 358 tatgtaatgtttg-catcacccg-acccttactggctcag-cctggctggtttta-catc 413 
I I I I I M M M M I M I I M I I I I I I M I I I I I I I I I I I I I I I M I M I I I I I I I I 
Sbjct: 678 tatgtaatgtttgccatcacccgcacccttactggctcagccctggctggttttaccatc 737 
Query: 414 atcgtgatg-cactggagct-gagtggctggatgtgg 448 
I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I 
Sbjct: 738 atcgtgatgccactggagctggagtggctggatgtgg 774 
51 
trrTiT.JTr..t;I".厂0 J u s
 .
 0
 . > 5
 V^
 n ^
 M t J I ^
 h丨二I
 “ ~ ^
 u
 . " T 。 T ^ _ . , 丨 — s
 二
 ： > .
 i
 - 、 ， -
 I t r
 
T




 . . w
 V :
 二二






































 I c t t r t t
 E r - l s ;





 - I I I
 -
 二 - I -
 - I - -


















 c i c
 . V -
 J L
 ) ： & 
f
 i ~ n j f . . X U T T "
 j •





< 」 . . M i , 、 i
 ； 「 。 u d j ^ 
g ^ _ _ ®
 ^ — F l ^ l ^ l h i
 ^
 、 ？ 丨 I — k
 ^ — — ^ — — ^ — — 8
 s — — 1 ! — — 。 、 ！
 一 y
 ,
 ^ ^ ^ 人
 -
J j









V . ！ ； ； —



















 I — - v . . i —


















^ fo ^ F p
 s 
Chapter 3: Results 
3.3.2 The primary and secondary structural analysis of hOAT2 
The 1647-nucleotide long hOAT2 cDNA contains an open reading frame 
that started from 96 and ended at 1742 from the mRNA sequence, and encodes a 
549-amino acid residue protein (Figure 3.3). The protein was predicted with a 
molecular mass of 60 kDa, and it appears to be slightly acidic with isoelectric 
point (pi) 6.60 as determined by a computer software DNASIS. 
An analysis of the primary amino acid sequence of hOAT2 using the Kyte 
and Doolittle (1982) algorithm predicts twelve a-helical transmembrane domains 
(Figure 3.4). Similar transmembrane domains pattern was obtained when using 
the Hoop and Woods model. There is a long extracellular loop consisting of 101 
amino acids between the transmembrane domain 1 and 2. The nonpolar rich 
residues with bulky side chains (Figure 3.5) such as leucine (17%), alanine 
(10%), valine (8%) and glycine (8%) made the protein highly hydrophobic, 
which are responsible in promoting the hydrophobic interaction within protein 
structures. The protein secondary structure was also predicted by Chou and 
Fasman method provided in the program DNASIS (Figure 3.6), together with the 
hydropathy plot, they are useful tools in designing immunogenic peptide for 
raising antibodies and it wi l l be described in the later chapter. 
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Figure 3.3 Nucleotide and amino acid sequences of the hOAT2 cDNA from 
the EMBL/GenBank accession number AF097518. The start and stop codons are 
shown in bold and asterisked respectively. 
9 18 27 36 45 54 
5 ' ATG G G C T T T G A G G A G C T G C T G G A G CAG G T G G G C G G C T T T G G G C C C T T C C A A C T G 
M e t G l y Phe G l u G l u L e u L e u G l u G i n V a l G l y G l y Phe G l y P r o Phe G i n L e u 
63 72 81 90 99 108 
C G G A A T G T G G C A C T G C T G G C C C T G C C C C G A G T G C T G C T A C C A C T G C A C T T C C T C 
A r g A s n V a l A l a L e u L e u A l a L e u Pro A r g V a l L e u L e u P r o L e u H i s P h e L e u 
117 126 135 144 153 162 
C T G C C C A T C T T C C T G G C T G C C G T G CCT G C C C A C C G A T G T G C C C T G C C G G G T G C C 
L e u P r o lie Phe L e u A l a A l a V a l Pro A l a H i s A r g C y s A l a L e u P r o G l y A l a 
171 180 189 198 207 2 1 6 
C C T G C C A A C T T C A G C CAT CAG G A T G T G T G G CTG G A G G C C C A T C T T C C C C G G G A G 
P r o A l a A s n Phe Ser H i s G i n A s p V a l T r p L e u G l u A l a H i s L e u P r o A r g G l u 
225 234 243 252 2 6 1 270 
C C T G A T G G C A C G C T C A G C T C C T G C C T C C G C T T T G C C T A T C C C C A G G C T C T C C C C 
P r o A s p G l y T h r L e u Ser Ser Cys L e u A r g Phe A l a T y r P r o G i n A l a L e u Pro 
279 288 297 306 315 324 
A A C A C C A C G T T G G G G G A A G A A A G G C A G A G C CGT G G G G A G C T G G A G G A T G A A C C T 
A s n T h r T h r L e u G l y G l u G l u A r g G i n Ser A r g G l y G l u L e u G l u A s p G l u P r o 
333 342 351 360 369 378 
G C C A C A G T G C C C T G C T C T CAG G G C T G G G A G T A G G A C C A C T C A G A A T T C T C C T C T 
A l a T h r V a l Pro Cys Ser G i n G l y T r p G l u T y r A s p H i s Ser G l u Phe Ser Ser 
387 396 405 414 423 432 
A C C A T T G C A A C T GAG T C C CAG T G G GAT C T G G T G T G T G A G CAG A A A G G T C T G A A C 
T h r lie A l a T h r G l u Ser G i n T r p A s p L e u V a l Cys G l u G i n Lys G l y L e u A s n 
441 450 459 468 477 486 
A G A GCT G C G T C C A C T T T C T T C T T C G C C GGT GTG CTG G T G G G G G C T G T G G C C T T T 
A r g A l a A l a Ser T h r Phe Phe Phe A l a G l y V a l L e u V a l G l y A l a V a l A l a Phe 
495 504 513 522 531 540 
G G A T A T C T G T C C G A C A G G TTT G G G CGG CGG CGT CTG CTG C T G G T A G C C TAG G T G 
G l y T y r L e u Ser A s p A r g Phe G l y A r g A r g A r g L e u L e u L e u V a l A l a T y r V a l 
549 558 567 576 585 594 
A G T A C C CTG G T G CTG GGC CTG G C A TCT G C A G C C T C C G T C A G C TAT G T A A T G TTT 
Ser T h r L e u V a l Leu G l y L e u A l a Ser A l a A l a Ser V a l Ser T y r V a l M e t Phe 
603 612 621 630 639 648 
G C C A T C A C C CGC A C C CTT A C T G G C T C A G C C CTG GCT GGT TTT A C C A T C A T C G T G 
A l a lie T h r A r g T h r Leu T h r G l y Ser A l a L e u A l a G l y Phe T h r lie lie V a l 
657 666 675 684 693 702 
A T G C C A CTG GAG CTG GAG TGG CTG GAT GTG GAG CAC CGC A C C G T G GCT G G A G T C 
M e t Pro L e u G l u L e u G l u T r p L e u A s p V a l G l u His A r g T h r V a l A l a G l y V a l 
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7 1 1 720 729 738 747 7 5 6 
C T G A G C A G C A C C T T C T G G A C A G G G G G C G T G A T G C T G C T G G C A C T G G T T G G G T A G 
L e u S e r S e r T h r Phe T r p T h r G l y G l y V a l M e t L e u L e u A l a L e u V a l G l y T y r 
765 774 783 792 801 810 
C T G A T A C G G G A C T G G C G A T G G CTT C T G C T A G C T G T C A C C C T G C C T T G T G C C C C A 
L e u lie A r g A s p T r p A r g T r p L e u L e u L e u A l a V a l T h r L e u P r o C y s A l a P r o 
819 828 837 846 855 864 
G G C A T C C T C A G C C T C T G G T G G G T G C C T G A G T C T G C A C G C T G G C T T C T G A C C C A A 
G l y lie L e u Ser L e u T r p T r p V a l P r o G l u Ser A l a A r g T r p L e u L e u T h r G i n 
873 882 891 900 909 918 
G G C C A T G T G A A A G A G G C C C A C A G G T A G T T G C T C C A C T G T G C C A G G C T C A A T G G G 
G l y H i s V a l L y s G l u A l a H i s A r g T y r L e u L e u H i s C y s A l a A r g L e u A s n G l y 
927 936 945 954 963 972 
C G G C C A G T G T G T G A G G A C A G C T T C A G C C A G G A G G C T G T G A G C A A A G T G G C C G C C 
A r g P r o V a l C y s G l u A s p Ser Phe Ser G i n G l u A l a V a l S e r L y s V a l A l a A l a 
981 990 999 1008 1017 1 0 2 6 
G G G G A A C G G G T G G T C C G A A G A CCT T C A T A G C T A G A C C T G T T C C G C A C A C C A C G G 
G l y G l u A r g V a l V a l A r g A r g Pro Ser T y r L e u A s p L e u Phe A r g T h r P r o A r g 
1035 1044 1053 1062 1 0 7 1 1080 
C T C C G A C A C A T C T C A C T G T G C T G C G T G G T G G T G T G G T T C G G A G T G A A C T T C T C C 
L e u A r g H i s lie Ser L e u Cys Cys V a l V a l V a l T r p Phe G l y V a l A s n Phe S e r 
1089 1098 1107 1116 1 1 2 5 1134 
T A T T A G G G C CTG A G T C T G GAT G T G T C G G G G C T G G G G C T G A A C G T G T A G C A G A C A 
T y r T y r G l y L e u Ser L e u A s p V a l Ser G l y L e u G l y L e u A s n V a l T y r G i n T h r 
1143 1152 1 1 6 1 1170 1179 1188 
C A G C T G T T G T T C G G G GCT G T G G A A C T G C C C T C C A A G C T G C T G G T C T A G T T G T C G 
G i n L e u L e u Phe G l y A l a V a l G l u L e u Pro Ser Lys L e u L e u V a l T y r L e u Ser 
1197 1206 1215 1224 1233 1242 
G T G C G C TAG G C A G G A CGC CGC C T C A C G C A A G C C G G G A C A C T G C T G G G C A C G G C C 
V a l A r g T y r A l a G l y A r g A r g L e u T h r G i n A l a G l y T h r L e u L e u G l y T h r A l a 
1251 1260 1269 1278 1287 1296 
CTG G C G T T C G G C A C T A G A CTG C T A G T G T C C T C C G A T A T G A A G T C C T G G A G C A C T 
L e u A l a Phe G l y T h r A r g L e u L e u V a l Ser Ser A s p M e t Lys Ser T r p Ser T h r 
1305 1314 1323 1332 1341 1350 
G T C CTG G C A GTG A T G GGG A A A GCT TTT TCT G A A GCT G C C T T C A C C A C T G C T T A G 
V a l L e u A l a V a l M e t G l y Lys A l a Phe Ser G l u A l a A l a Phe T h r T h r A l a T y r 
1359 1368 1377 1386 1395 1404 
C T G T T C A C T T C A GAG TTG TAG CCT A C G GTG C T C A G A CAG A C A G G G A T G G G G CTG 
L e u Phe T h r Ser G l u Leu T y r Pro T h r V a l L e u A r g G i n T h r G l y M e t G l y L e u 
1413 1422 1431 1440 1449 1458 
A C T G C A CTG G T G G G C CGG CTG GGG G G C TCT TTG GCC C C A CTG G C G G C C T T G C T A 
T h r A l a L e u V a l G l y A r g L e u G l y G l y Ser Leu A l a Pro L e u A l a A l a L e u L e u 
1467 1476 1485 1494 1503 1512 




I Chapter 3: Results 
r 
I 
i A s p G l y V a l T r p L e u Ser L e u Pro Lys L e u T h r T y r G l y G l y lie A l a L e u L e u 
\ 
I 1 5 2 1 1530 1539 1548 1557 1 5 6 6 
\ G C T G C C G G C A C C G C C C T C C T G C T G C C A G A G A C G A G G C A G G C A C A G C T G C C A G A G 
A l a A l a G l y T h r A l a L e u L e u L e u Pro G l u T h r A r g G i n A l a G i n L e u P r o G l u 
1 5 7 5 1584 1593 1602 1 6 1 1 1620 
A C C A T C C A G G A C G T G G A G A G A A A G A G T G C C C C A A C C A G T C T T C A G G A G G A A G A G 
T h r lie G i n A s p V a l G l u A r g Lys Ser A l a Pro T h r Ser L e u G i n G l u G l u G l u 
\ 1629 1638 1647 
A T G C C C A T G A A G C A G G T C C A G A A C T A A 3‘ 
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Figure 3.4 Hydropathy analysis based on the algorithm of Kyte and Doolittle 
using a window setting of 8. The putative transmembrane spanning domains are 
numbered in the corresponding regions. 
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Figure 3.5 The amino acid content of hOAT2. Leucine, alanine and valine 
accommodate a high percentage of residues among the total 548 amino acids and 
thus contribute to the hydrophobic property of the protein. 
Amino Acid Count Mol% 0 10 20 30 40 
A l a A 55 1 0 . 0 3 H 
Arg R 3 4 6.2 0 — 
A s n N 8 1 . 4 5 ^ 
A s p D 14 2 . 55 « 
Cys C 9 1 . 6 4 胃 
Gin Q 2 0 3 . 6 4 酬 
G l u E 3 1 5 , 6 5 — 
Gly G 4 4 8. 02 
His H 10 1.82 鼸 
l i e 工 1 0 L 8 2 « 
Leu L 92 16« 78 
Lys K 9 1.64 “ 
Met M 9 1.64 ® 
Phe F 25 4 - 5 6 翻 
Pro P 28 5.10 圓 
Ser S 4 0 7.29 
Thr T 35 6.38 
T r p W 13 2 . 3 7 -
Tyr Y 16 2.91 -
Val V 46 8.39 
Asx B 0 0,0 0 
GIk Z 0 0,0 0 
* * * * 0 0 . 0 0 
Xxx X 0 0.00 I I I I I 
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Figure 3.6 The protein secondary structure prediction of hOAT2 by DNASIS 
using Chou and Fasman method (beta-turn probability value 75 x lOe-1). H(h): 
hel ix-tum-helix; S(s): sheet; T(t): turn; and C(c): coil. 
10 20 30 40 50 60 70 
MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLMVPAHRCALPGAPANFSHQDVWLEAHLP 
HELIX HHHHHHHHhh h hhhHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHh hhhHHhhhhHHHHHH 
SHEET ssssssss s ssssssssssssssssssssssssssssss SSSSs 
TURN TTTTTTTTT TTTTTTTT 
COIL 
80 90 100 110 120 130 140 
REPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYDHSEFSSTIATESQWDLVCEQ 
HELIX Hh hh hhhhhhhhhhhhhHHHHHh hHHHHHHH hhhhHHHHHHHHHHHHh 
SHEET ss sSSSSSSSssssSs sss sSs sssssssssssssssss 
TURN T T m r m T TTTT TTTTT TTTTTTT TTTT TTTT T 
COIL C 
150 160 170 180 190 200 210 
KGLNRAASTFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYVSTLVLGLASMSVSYVMFAITRTLTGSALA 
HELIX h HHHhhhhhhhhhhhhhhhhh hhhhhhhhhhhhhHHHHHHhhhhhhhhhhhhhhhHHH 
SHEET SSSSSSSSSSSSSSSSs sssSSSSSSSSSSSSSs SSSSSSSSSSSss ss 
TURN TTT TTTTTTTTT TTTT 
COIL CC 
220 230 240 250 260 270 280 
GFTIIVMPLELEWLDVEHRTVAGVLSSTFWTGGVMLLALVGYLIRDWRWLLLAVTLPCAPGILSLWWVPE 
HELIX HHHHHHHHHHHHHHHHHHHhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhH hhhhhhhhh 
SHEET ssssssssssssssss SSSSSssssSssssSSSSSSSSSSSSSSSSSSSSSSsSS sSSSSSs 
TURN TTTT TTTT TTTT TTT 
COIL 
290 300 310 320 330 340 350 
SARWLLTQGHVKEAHRYLLHCARLNGRPVCEDSFSQEAVSKVMGERWRRPSYLDLFRTPRLRHISLCC 
HELIX hHHhhhhhhhHHHHHHhhhhHHHh hhHHHHHHHHHHHHHH hhhhh 
SHEET SSSsssss SSSSs Ss sSSSSs SSSSS 
TURN T TTTT TTTTT TTTTTT TTTTT TTTT 
COIL C CC 
360 370 380 390 400 410 420 
WWFGVNFSYYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVYLSVRYAGRRLTQAGTLLGTALAFGTR 
HELIX hhhhhhhhh hhhhhhhhhhHHhhhhhhhhhhH hhhhhhhhhhhhhhh 
SHEET SSSSSSSss ssSSSssssSSSSSSSSSSSSSSs SSSSSSsSssssSSSssssSSSSSSSSSSS 
TURN TTTTTT TTTT TTTT TTTT TTTT 
COIL 
430 440 450 460 470 480 490 
LLVSSDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRqTGMGLTALVGRLGGSLAPLAAIJLDGVW 
HELIX hhh hhhhhhhhhHHHHHHHHHhhhhhhhhhhhhhhhhhhh hhhhhhhhh hHHHHHHHHHHH 
SHEET SSs SSSSSSSs SSSSSSSSSSSSSSSSSss ssSSSSSSs sssssssss 
TURN TTTTTTT TTTTTT TTTTT 
COIL 
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500 510 520 530 540 
LSLPKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEEMPMKQVQN 
HELIX HHHmhhhhHHHHHHHHHHHHHHHHHHHHHHHHHH™ hHHHHHHHHHHH 
SHEET sssssssssssssssssssssssssssssssssssss ss sssssss 
TURN TTTT TTTTT 
COIL CC C 
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3.3.3 Motif search and prediction 
Protein sequence analysis ofhOAT2 from PROSCAN (Bairoch et al., 1997) 
predicted seven different patterns (Table 3.1). There are three possible N-
glycosylation sites (N-{P}-[ST]-{P}) at positions Asn^^ Asn^^ and Asn^^^ where 
{P} indicates that proline is not applicable. Statistical analysis has revealed that 
the proline residue between the Asn and Ser/Thr wi l l inhibit the N-glycosylation 
(Bause, 1983). Two of these potential N-glycosylation sites (Asn^^ and Asn^') are 
located in the long extracellular loop between transmembrane regions 1 and 2. 
The carbohydrate chain is attached to the Asn residue i f it is in the context of -
Asn-X-Ser / Thr- and accessible to the glycosylation machinery localized in the 
lumen of the ER (Kornfeld and Kornfeld, 1985; Pfeffer and Rothman, 1987). 
Another interesting finding includes two leucine zipper patterns are deduced 
whereas this structure often occurs in numerous eukaryotic regulatory proteins 
and a few in prokaryotic proteins only. The leucine zippers are located near the 
carboxyl-terminal of the sequence, while the latter one is found within the 
sequence 461 — 482bp, which is placed within the predicted eleventh and the 
predicted twelfth membrane-spanning domains. In regard to the leucine zipper 
pattern often presents in nuclear DNA-binding proteins, it seems to be 
contradicted i f hOAT2 protein is located within the plasma membrane. However, 
61 
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the high leucine content (totally 92 leu) in this protein probably contributes to 
such prediction of these leucine-zipper patterns, in other words, this predicted 
result was just occurred by chance only. 
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Table 3.3 Protein sequence analysis based on the prediction from 
PROSCAN, a total of seven different patterns are proposed. 
Name Pattern Site 
N-glycosylation N-{P}-[ST]-{P} 5 7 - 6 0 INFSH 
9 1 - 9 4 NTTL 
358-361 NFSY 
cAMP- and cGMP-dependent [RK](2)-x-[ST] 330 - 3 3 3 R R P S 
protein kinase phosphorylation 402 - 405 RRLT 
Protein kinase C [ST]-x-[RK] 166 - 1 6 8 S D R 
phosphorylation 281 -283 SAR 
340 - 342 TPR 
396 - 398 SVR 
Casein kinase I I [ST]-x(2)-[DE] 59-62 SHQD 
phosphorylation 93 - 96 TLGE 
100 - 103 SRGE 
132 - 135 SQWD 
333 - 336 SYLD 
523 - 526 TIQD 
535 - 538 SLQE 
N-myristoylation "G- 53 - 58 GAPANF 
{EDRKHPFYW} 75 - 80 GTLSSC 
-x(2)-[STAGCN]- 142 - 147 GLNRAA 
{P} 154- 159 GVLVGA 
186-191 GLASAA 
206-211 GSALAG 
233 -238 GVLSST 
356 - 361 GVNFSY 
370 - 375 GLGLNV 
408 -413 GTLLGT 
412-417 GTALAF 
465 - 470 GMGLTA 
488 - 493 GVWLSL 
Amidation x-G-[RK]-[RK] 169- 1 7 2 ~ F G R R 
400 - 403 AGRR 
Leucine zipper pattern L-x(6)- L-x(6)- 366- 3 8 7 ~ L D V S G L G L N V Y 
L-x(6)- L-x(6) QTQLLFGAVEL 
461 - 4 8 2 LRQTGMGLTAL 
IVGRLGGSLAPL 
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3.3.4 Homology alignment 
Homology matching analyzed by BLAST 2 sequence from NCBI and 
DNASIS revealed maximum identities between rat and human 0AT2 of 82% 
(1318/1597) in nucleotide sequences and 77% in amino acid sequences (Figure 
3.7). 
The amino acid sequences of the four members of human organic anion 
transporter subfamily, including hOATl to hOAT4 were compared. The 
percentage of identity among the sequences is tabulated as below (Table 3.4). 
There is only a fair identity ofhOAT2 to hOATl, hOAT3 and hOAT4 (38%, 35%, 
37% respectively). Instead, the most homologous pair is observed (90%) between 
hOAT3 and hOAT4, which are located predominantly in kidney and placenta 
(Cha et al., 2000; Race et al, 1999) respectively. 
Table 3.4 Comparison of amino acid sequence identities among the four 
members in human OAT family 
QAT2 OAT3 OAT4 
OATl ^ ^ 
OAT2 35% 37% 
OAT3 90% 
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Figure 3.7 The amino acid sequence alignment between rat and human 0AT2 
with 77% (425/541) sequence identity. 
H0AT2 1 MGFEELLEQVGGFGPFQLRN-VALLALPRVLLPLHFLLPIFLAAVPAHRC 50 
I I I I I I 丨 I I I m I I I I I I 1.1 丨丨 I I I I I I I I I I I I I I I 丨 
R0AT2 1 MGFEDLLDKVGGFGPFQLRNLV-LMALPRMLLPMHFLLPVFMAAVPAHHC 50 
H0AT2 51 ALPGAPANFSHQDVWLEAHLPREPIX3TLSSCLRFAYPQALPNTTLGEERQ 100 
I m I I I 丨 I I 丨 I I I I I I I I I I I I I I I I I I I I I I II I I I I 
R0AT2 51 ALPGAPANLSHQDLWLEAHLPRETDGSFSSCLRFAYPQTVPNVTLGTEV- 100 
H0AT2 101 SR-GELEDEPATVPCSQGWEYDHSEFSSTIATESQWDLVCEQKGLNRAAS 150 
I 丨 I I j I 11111111 m I m I m 11 11111 i i i i i 
R0AT2 101 SNSGEPEGEPLTVPCSQGWEYDRSEFSSTIATE--WDLVCQQRGLNKITS 150 
H0AT2 151 TFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYVSTLVLGLASAASVSYVMF 200 
I 11 1111111 i m m m m m m 11111 MM 丨丨丨 
R0AT2 151 TCFFIGVLVGAWYGYLSDRFGRRRLLLVAYVSSLVLGLMSAASINYIMF 200 
H0AT2 201 AITRTLTGSALAGFTIIVMPLELEWLDVEHRTVAGVLSST-FTOGVMLL 250 
I I 11 I 11 I M I I I I I I I I I I I I I I I I I I I I I I I I I I I 11 I I I 
R0AT2 201 WTRTLTGSALAGFri IVLPLELEWLDVEHRTVAGVIS-TVFWSGGVLLL 250 
H0AT2 251 ALVGYL™WRWLLLAVTLPCAPGILSLWWVPESARWLLTQGHVKEAHRY 300 
I I I I I I I I I m I I I MM I I I I I I I I I I I I I I I I I I I I I I 
R0AT2 251 ALVGYLIRSWRWLLLAATLPCVPGIISIWWVPESARWLLTQGRVEEAKKY 300 
H0AT2 301 LLHCARLNGRPVCEDSFSQEA---VSKVAAGERWRRPSYLDLFRTPRLR 350 
I I I I m m I j MM I I 11 I I I I I I I I I I I I 
R0AT2 301 LLSCAKLNGRPVGEGSLSQEALNNV- -VTM-ERALQRPSYLDLFRTSQLR 350 
H0AT2 351 HISLCCVWWFGVNFSYYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVY 400 
m m m m m m i m m m m m m m m 丨丨 
R0AT2 351 HISLCCIMFGVNFSYYGLTLDVSGLGLNVYQTQLLFGAVELPSKIMVY 400 
H0AT2 401 -LSVRYAGRRLTQAGTLLGTALAFGTRLLVSSDMKSWSTVLAVMGKAFSE 450 
丨丨丨丨丨丨1丨II丨丨丨11 I I I M M I I I I I I m m 
R0AT2 401 FL-VRRLGRRLTEAGMLLGAALTFGTSLLVSLETKSWITALVWGKAFSE 450 
H0AT2 451 AAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLAPLAALLDGVWLSL 500 
I I I I I IMMMMMMMM Mi l l MM I I I l l l l l l i l l l I 
R0AT2 451 AAFITAYLFTSELYPTVLR(^GLGLTALMGRLGASLARLAALLDGVWLLL 500 
H0AT2 501 PKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEEMPM 550 
I I MUM I I I I I I I I I I I I M I I I I I I I I I I I I I I 
R0AT2 501 PKVAYGGIALVAACTALLLPETKKAQLPETIQDVERKS--T--QEED-- - 550 
H0AT2 551 KQVQN 600 
1 
R0AT2 551 --V* 600 
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Figure 3.8 The amino acid sequence of hOAr2 contains 549 residues. The 
three A^-glycosylation sites were predicted and labeled as bolded letter "N". The 
twelve putative membrane-spanning regions are underlined and bolded. In 
addition, two leucine zipper patterns L-x(6)-L-x(6)-L-x(6)-L-x(6) which labeled 
in red are identified and the latter one is located within eleventh and twelve 
transmembrane domains. 
NHs -
MGFEELLEQV GGFGPFQLRN VALLALPRVL LPLHFLLPIF 
LAAVPAHRCA LPGAPi\NFSH QDVWLEAHLP REPDGTLSSC 
LRFAYPQALP NTTLGEERQS RGELEDEPAT VPCSQGWEYD 
HSEFSSTIAT ESQWDLVCEQ KGLNRAASTF FFAGVLVGAV 
AFGYLSDRFG RRRLLLVAYV STLVLGLASA ASVSYVMFAI 
TRTLTGSALA GFTIIVMPLE LEWLDVEHRT VAGVLSSTFW 
TGGVMLLALV GYLIRDWRWL LLAVTLPCAP GILSLWWVPE 
SARWLLTQGH VKEAHRYLLH CARLNGRPVC EDSFSQEAVS 
KVAAGERWR RPSYLDLFRT PRLRHISLCC VWWFGVNFS 
YYGLSXDVSG LGXNVYQTQI, LFGAVEJLPSK LLVYLSVRYA 
GRRLTQAGTL LGTALAFGTR LLVSSDMKSW STVLAVMGKA 
FSEAAFTTAY LFTSELYPTV LRQTGMGLTA LVGRXGGSLA 
PLAALLDGVW LSLPKLTYGG lALLAAGTAL LLPETRQAQL 
PETIQDVERK SAPTSLQEEE MPMKQVQN - H〇〇C 
Table 3.5 The corresponding positions of transmembrane helices 
Helix [ 1 2 3 4 5 6 7 8 9 10 11 12 
Begin 21 “""“146"“174 204 230 259 346 375 404 433 465 493 
End 44 166 198 224 250 278 366 395 424 453 485 512 
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3.4 Chromosomal mapping of hOAT2 gene 
3.4.1 Somatic cell hybrid mapping of hOAT2 gene 
By somatic cell hybrid mapping (monochromosomal NIGMS 
Human/Rodent Somatic Cell Hybrid Mapping Panel 2-version 3), the 
chromosomal location of hOAT2 in human was investigated. The PGR products 
synthesized from somatic cell hybrid contained chromosome (Human line 
IMR91) 1 to 22, X and Y were loaded on 2% agarose gel. With refer to Figure 
3.9, an individual distinct band of about 900 bp, which was amplified from cell 
hybrid DNA retaining human chromosome 6 (NA10629), was yielded with 
closest molecular size to human DNA rather than mouse or hamster DNA 
controls. It indicated the hOAT2 gene was mapped on chromosome 6. 
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Figure 3.9 PGR screening of a panel of 24 somatic cell hybrid DNAs 
(human/rodent somatic cell hybrids mapping panel 2-version 3; National Institute 
of General Medicine Service, Coriell Cell Repositories). The labels indicate on 
the top of each lane representing the human chromosome number retained in the 
somatic cell hybrids. Human, mouse and hamster genomic DNA are shown. A 
band of expected size 〜1-kb was generated from chromosome 6 and human 
genomic DNA control. DNA size marker is DNA Ladder Plus (MBI Fermentas). 
Uh 
^ g 22 ^ 
^ • — c \ m 、r‘ \o 卜 GO c^ .o 产 c i ‘ h 
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3.4.2 Radiation hybrid mapping of hOAT2 gene 
For deeper investigation for the location of hOAT2, we performed radiation 
hybrid mapping containing 93 hybrid genomic DNAs. After analyzing the PGR 
products by gel electrophoresis (Figure 3.10), we obtained a set of numbers 
composed of “0 ” and "1" which represented the non-existence and existence of 
positive band. The data generated is shown as follow: 10000 00100 00100 00100 
01000 10010 11011 11100 01100 10000 00000 11001 01101 00011 00111 01000 
11010 00000 000. The screening results were processed by the software 
RHMAPPER at the Whitehead Institute / MIT Center for Genome Research. The 
returned output is shown in (Figure 3.11). With reference to the threshold value 
>15, the hOAT2 gene was found to locate on 0.50cR (LOD>2.5) upper to 
framework marker D6S271, and S.OlcR lower to framework marker WI-5971, 
which is equivalent to 249.63 cR from top of Chromosome 6 linkage group. 
Since the D6S271 marker had already been mapped on 6p21.1 -> p2L2 to which 
the corresponding location of hOAT2 could be deduced. 
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Figure 3.10a PGR screening on radiation hybrid panel composed of 93 genomic 
hybrid DNA from human and hamster somatic cell lines. The samples were 
analyzed on 2% agarose gel，human and hamster DNA controls were included. 
The presence of a band which has an identical size to human control is scored as 
“1”，the absence is scored as “0” . PGR products amplified from hybrid DNA 1 — 
48 were shown. 
b a S 
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Figure 3.11 A partial RH map from Whitehead Institute showing the 
placement data relative to framework for human chromosome 6. The hOAT2 was 
placed within two framework markers, 0.50 cR (LOD > 2.05) upper to D6S271 
and 8.01 cR lower to WI-5971. Since the closet position of hOAT2 to the 
framework marker D6S271, which was mapped 249.63 cR from top of 
chromosome 6 linkage group，a location of 6p21.1 21.2 was identified for 
hOAT2. 
10 ？！ — CHLC.GATA'UJD3.7« 
：“ . D6S2TJ ^ ^ _ WI-533T 
I i ^ r z ^ ^ z — wi-c«o 
Q o = ~ ^ H Z Z ^ W I - 4 1 S C 
^ — ~ W I - 5 7 1 8 
1<5.3 ^ Z Z ^ T ^ — W I - 3 9 9 5 
—I^ZZ" WI-5971 
： ： 二 三 二 一 = = : - ^ D6S271 
12.2 ^ I I Z Z L ^ W I - 謝 2 
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3.4.3 Identification of partial human genomic sequence 
The 1-kb genomic PGR product form the positive human control was 
subcloned in TA cloning vector and sequenced using M l 3 reverse primer as 
described in MATERIALS AND METHODS. It was matched with our 
expectation that the 〜1-kb genomic DNA possessed the cDNA sequence of 
hOAT2 gene. Concomitantly two introns were identified with size 655-bp and 
134-bp respectively and the nucleotide sequences were shown in figure 3.12. 
The whole intron-exon distribution of hOAT2 was later deduced after a 
human genomic clone RP11-117C11 (Accession number: AC026532) was being 
published. Under the High Throughput Genomic (HTG) Blast search in NCBI, 
the mRNA sequence of hOAT2 matched in segments of this genomic clone in 
high identities (percentages). The length of the genomic sequence deduced from 
the hOAT2 mRNA was approximately 6.8 kb and also nine introns were being 
deduced accordingly. The former identified two intron sequences were found to 
be located within exon 2 and 4. The schematic diagram presenting the intron-
exon distribution is shown in figure 3.13. 
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Figure 3.12 The partial genomic sequence of hOAT2 gene. Two introns were 
identified and sequenced which shows in bold italic letters. The boxes indicated 
the forward and reverse primers used in the radiation hybrid mapping and the 
unbold letters represented the coding sequence of hOAT2. 
IGGCTGGGAGT ACGACCACTC AGAA|TTCTCC T C T A C C A T T G CAACTGAGGT 
ACTTAAGCCC AGAAGTTGAG AGACATGTGA GAGGGATGGG CCTGCCATTT 100 
CCTTGGGTGG TTACTGTGTA GCCTATTAGA TGTATTACTT TACCTCTTAA 
AGTCTCAGTT TACCAATCTG TAGATGGGGG CTATGAATAT AAGGCACTTT 200 
TAGTTCATGG CTTGTAGTAA CAGGATCCTA CACAAGAACT ATTATCATCA 
TCATTAATTT GGAGGTGATT AAGGCAGGGA AGGGCTAAAG TGGCTTCAGG 300 
GAGTTGAGAC AAAGAGCTGA GAAGGCAATT TCTGCAGCAA GAGGTGGAGA 
AACAATAGAG CCCTTCTTTT CTCCCCTTCC TCTTTTCCAA TCCCAGGTCT 400 
GTATTTACAT AATCCATCTT GAGGTGGAAT GTCGGTGGAG GCAGTCTCCC 
TGGGAGGCAG CAGGTCGAGG CCTTCCTTGG GAAGAAGCTG AGGCTGCAGG 500 
ACTGGGGAGG GACAAAGTTT CCTATTCCCC AAGCTGGCGT GAATCGTTGG 
GAGGTTTATT ATCTGGCATG GAGGTACCAG AATGGCAGAG TTCGCCTCAG 600 
AAGGCTCCAG GGTCTGGAGA GGAGGAGCTG GTGCCTGCTG GAAAGGGGCT 
GATGTTCATA GGAGGTCCCT TTCTGCCTGT CCTRGCAGTG GGATCTGGTG 7 0 0 
TGTGAGCAGA AAGGTCTGAA CAGAGCTGCG T C C A C T T T C T TCTTCGCCGG 
TGTGCTGGTG GGGGCTGTGG CCTTTGGATA TCTGTCCGAC AGGTGGGGTG 8 0 0 
AGGCACTGGG CCAATAAGAA ACTGGCTGGG GGAACTTTCT CCCACTAGCT 
GGGGTATGAG CCTAGTCTAC CTATGCCTTA GAACCTCCTT CCACAGGGAA 900 
CTGACCCTGC ATGACCCCTT TGCAGGTTTG GGCGGCGGCG TCTGCTGCTG 
GTAGCCTAC|G TGAGTACCCT GGTGCTGGGC CT| 
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Figure 3.13 Schematic diagram showing the intron-exon distribution which 
was determined between the hOAT mRNA sequence and the partial genomic 
sequence from a Homo sapiens clone RP11-117C11 (Accession Number: 
AC026532). Ten exons were identified and they are shown in black boxes, where 
the 5' and 3, untranslated regions are indicated in gray. 
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3.5 Detection of the hOAT2 gene expression in human tissues by RT-
PCR assay 
A PCR-based analysis was carried out on three human MTC panels: adult, 
fetal and cancer. PCRs were performed on first-strand cDNA from various 
human tissues, after that the products were analyzed in 1% agarose gel. For 
human normal adult panel, sixteen human tissues were chosen in the test. In the 
figure 3.14, a positive band was highly detected in liver and another band 
showed less weakly in kidney, no non-specific binding was found in other tissues. 
This finding was similar to that of rat in which the gene is preferentially 
expressed in liver and low levels in kidney (Simonson et al, 1994). H0AT2 
transcript was not found in heart, brain, placenta, lung, skeletal muscle, pancreas, 
spleen, thymus, prostate gland, testis, ovary small intestine, colon, or leukocyte 
even at lower annealing temperature (data not shown). 
We have also used another MTC panel in order to determine the expression 
pattern in human fetus. Eight different human fetal tissues were analyzed in this 
panel. From this, only a single dominant transcript was detected in fetal liver 
(Figure 3.15). No positive signal was appeared in fetal kidney, or other fetal 
tissues including brain, lung, heart, skeletal muscle, spleen or thymus. 
The expression of hOAT2 was also found in human liver tumor as shown in 
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figure 3.16 by amplifying the specific transcript from liver tumor first-strand 
cDNAs (Invitrogen). Nevertheless, the same pattern was not reported in other 
carcinomas from human cancer MTC panel (Data not shown). 
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Figure 3.14 RT-PCR analysis on human normal adult MTC panel 
demonstrating the tissue distribution for hOAT2. Strong expression was detected 
in liver relative to kidney to produce a transcript size at 〜1.6-kb which was 
identical to the positive control. Normalization using housekeeping gene 
GAPDH showed a 550-bp band in all tissues. 
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Figure 3.15 RT-PCR analysis on human fetal MTC panel demonstrating the 
tissue distribution for hOAT2. Expression was only detected in liver producing a 
transcript size at ~1.3-kb. Normalization was performed using G3PDH which 
produced a band of ~ l -kb in all tissues. 
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Figure 3.16 PCR detection of hOAT2 partial sequence from human normal 
liver and liver tumor first-strand cDNA producing a transcript size approximately 
at 1.3-kb. Expression from both tissues was shown in the figure. 
丄 。 4 X , 、 
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3.6 Determination of subcellular localization of hOAT2 protein by 
conjugating fluorescence protein 
The hOAT2 gene in frame with the green fluorescent protein sequence was 
transfected into C2C12 mammalian cells. Subcellular localization of these fusion 
proteins GFP-hOAT2 was examined under confocal microscope. Figure 3.17 
shows that the fluorescence (488nm excitation, 509mn emission) was uniformly 
distributed in the cytosolic compartment but excluded from the nucleus and the 
membrane structures. 
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Figure 3.17 Fluorescence images of h O A H conjugated with GFP in a. C2C12 
and b. HepG2 cells by confocal microscope. Cytosolic localization of the fiision 
proteins is clearly observed. Scale bar, 5|am in all fluorescence images. 
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3.7 Immunodetection of protein extracts from cultured cells 
Polyclonal antibodies against hOAT2 were utilized for testing various 
protein extracts. Mammalian cells Hep3B was one of them used in testing against 
the anti-hOAT2 antibodies. Both lanes showed in figure 3.18 were loaded with 
extracted proteins from Hep3B in different amount. Discrete bands are observed 
in both lanes with protein size around 60kDa. Whether recognition of anti-
hOAT2 antibodies to other normal tissues or cancer cells needs further 
investigation. 
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Figure 3.18 Immunohybridization using polyclonal anti-hOAT2 antibody 
detected a band approximately 60kDa in Hep3B total proteins (25\ig / 50|Lig). 
50|ag 25|Lig 
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4 Chapter 4: Discussion 
4.1 Characterization of the hepatocellular ESTs 
4.1.1 Classification and frequency distribution of the 500 ESTs 
Under the sequence alignment search in BLAST, one should concern 
whether a given alignment constitutes evidence for homology, and is not the 
outcome by chance alone. To lower the possibility in case of aligned 
sequences that are generated randomly from the DNA or protein pool, a 
statistical Poisson 尸-value was utilized to figure out the reliability of those 
alignments (Altschul and Erickson, 1985; Fitch, 1983; Lipman et al., 1984). 
For example, a P-value < 0.01 can say reliably as i f 100 random alignments 
have score inferior to the alignment of interest. 
The 500 ESTs presented in this project were a combination of 
sequences generated from two cDNA libraries, human normal liver and 
human cancerous liver as shown in the Table 3.1. It seems that the number 
of 500 might not be sufficient for representing a significant gene expression 
pattern of these tissues, it could more or less, give us an insight to the 
distribution of ESTs. Upon non-redundant search of the 300 normal liver 
ESTs, 224 of them (75%) matched with known genes, 43 (14%) of them 
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matched with novel genes and the remaining 33 (11%) of them were 
regarded as mitochodrial genes. On the other side, similar pattern was likely 
to be observed in the 200 liver tumor ESTs, whereas 67% (134) of known 
genes, 23% (46) of novel genes and the last 10% (20) was grouped into the 
mitochondrial category. It could be seen that there are relatively low 
percentages of genes that were identified as novel when compared with data 
from the last few years. It implies that the exploration of genes is 
exponentially increasing in this appreciable period, with the aid of improved 
sequencing technique, instruments and advanced information technologies. 
Identified known genes, in accordance with their main functions, were 
further divided into eleven subgroups as described previously in Table 3.2. 
The overall distribution of ESTs between these two libraries was roughly 
similar except two categories, transcription / translation proteins and 
secretory proteins. An extraordinary high abundance of transcription / 
translation proteins in cancer liver (31.3%) than in normal (3.1 %), might 
link to the rapid and frequent divisions of cancerous cells which requires 
active synthesis of cellular materials such as nuclear DNA and structural 
components. A comparatively large discrepancy existed in the expression of 
secretory proteins, though it was quite abnormal to see such a high 
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frequency in normal liver (65.2%) because such unexpected high frequency 
of secretory proteins is not observed in other liver EST library (Adams et al., 
1992). Thus note to this point, it is necessary for us to generate significant 
number of ESTs before coming to any conclusion. 
4A.2 The expression pattern of membrane associated proteins 
This large-scale liver ESTs sequences are the cooperative works 
contributed by many members in our laboratory. The gene frequency 
distribution classification are compatible with the one performed by my 
colleague (C.H. Yu, M.Phil thesis). The ESTs encoding membrane-
associated proteins only accommodates low percentages for normal (3.3%), 
tumor-normal (3.6%) and tumor (2%) EST libraries. The low abundance of 
membrane-associated ESTs expressing in these liver tissues might represent 
the characteristic physiological and regulatory functions of this organ. For 
example, a rather high abundance of membrane-associated proteins in 
human brain (15.3%) (Adams et al., 1993) is likely related to its blood-brain 
barrier to provide limited substrates, hormones or ions across the brain, plus 
the huge energy consumption via Na+K+ATPase which transport Na+ and K+ 
across plasma membranes. 
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4.2 Tissue distribution and expression profiles of hOAT2 
RNA blot analysis revealed that rat 0AT2 protein has a strong 
expression in liver and relatively weak expression in kidney (Simonson et 
al., 1994). In order to examine the expression pattern of human 0AT2, 
Northern blot analysis was performed. Unfortunately, our multiple tissue 
blot did not show hOAT2 expression. Multiple bands of irrelevant transcript 
sizes and also weak expression were detected. This discrepancy in the 
Northern blot analysis may not be attributed to the specificity of the DNA 
probes, since probes constructed from different regions of the cDNA had 
been selected. We chose the 5'-coding region of hOAT2 of sizes 243 and 
570 that had < 40% identities to hOATl, hOAT3 and hOAT4. For this 
reason, we make use of RT-PCR (Clontech) for the expression studies. It 
has the advantage of high sensitivity, and it is possible to detect some rare 
transcripts that cannot be determined in Northern blots. As shown in figure 
3.14, hOAT2 was detected at a high level in liver and at a lower level in 
kidney, obviously, the result was consistent to what was determined in rat. 
In comparing with other human OAT members, where hOATl and 
hOAT3 were determined as kidney-specific proteins (Race et al., 1999) and 
hOAT4 was expressed in both kidney and placenta (Hosoyamada et al, 
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1999), a common characteristic could be seen from these expression profiles 
including hOAT2. Interestingly, the kidney seems to be unique for all of the 
four organic anion transporters, though some of them were not 
predominantly expressed in that particular organ. Whether the existence of 
common substrate(s) exists between the four members need further 
experimental studies. 
Other types of transport proteins such as Ntcp, oatpl and OCT were 
found to be located at the sinusoidal hepatocyte membrane (Kullak-Ublick, 
1999) where rOAT2 is also expressed in that region (Simonson et aL, 1994). 
Nevertheless, the substrate specificities among these transporters are quite 
divergent. Ntcp and oatpl were believed to be bile acid transporters, which 
mediates the Na+-dependent hepatocellular uptake of conjugated bile acids 
such as taurocholate, and Na+-independent uptake of taurocholate, cholate, 
anionic steroid conjugates (Jacquemin et al., 1994). 
4.3 HOAT2 in fetal development 
The pattern of expression of the rat 0AT2 gene in liver development 
had been demonstrated by Simonson et al. (1994). At the fetal stage, the 
level of expression was very low, however it dramatically increased at the 
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time of birth and remained active throughout adulthood (Simonson et al., 
1994). Amplification of human fetal multiple tissue cDNA revealed that the 
hOAT2 transcript was expressed in fetal liver but was absent in fetal kidney. 
It is different from previous results where hOAT2 was expressed in both 
human adult liver and kidney. In our knowledge, it is the first finding 
showing differential expression of hOAT2 in fetal and adult kidney. Such 
prior maturation of liver to kidney might suggest that there is a higher need 
for the removal of various organic compounds by enterohepatic circulation 
than in kidney (Gregus Z., 1991). 
4.4 Predicting the topology of membrane proteins 
Many of the transport proteins are believed, on the basis of their amino 
acid sequences and hydropathy plots, to have multiple membrane-spanning 
helical regions. Theoretical prediction algorithms have been found to be 
useful in detecting membrane-spanning regions from the primary structure 
alone. One of the most common use methods is adopted by Kyte and 
Doolittle (1982). The calculation is involved the mean residue 
hydrophobicity values obtained for consecutive 19-residue spans, where 
segments with hydrophobicity above a certain threshold are predicted to be 
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membrane-spanning. 
Topology prediction of hOAT2 showed twelve transmembrane 
segments as described in figure 3.4 and table 3.5. In addition to a large 
extracellular loop (101 amino acids) on the region between the putative 
transmembrane domains one and two, a comparatively smaller intracellular 
loop with 67 amino acid residues is located between domains six and seven. 
It is generally believed that the recognition of extracellular substrates or 
anions requires the interacting hydrophilic surfaces, such as those present in 
the N-terminus and the extracellular loop. So far, both the hydrophilic N-
terminus and C-terminus of hOAT2 are predicted to be located in the 
intracellular compartment, the discrete hydrophilic loop becoming the focus 
for the transporter in substrate recognition and even its multispecificity. 
It should be noted that these assignments of topology should be 
considered tentative until direct structural determination, such as X-ray 
diffraction analysis or electron microscope scanning, has been performed. 
4.5 Chromosomal mapping of human OAT2 
Radiation hybrid (RH) mapping makes use of somatic cell genetic 
approach using a random set of irradiated human donor cells to non-
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irradiated hamster cells. In the GeneBridge 4 RH mapping panel, 
approximately 30 % on average of the donor genomic DNA is stably 
retained in the hamster cells. A 3000 rad of X-ray dosage is applied in 
constructing the RH map with the average fragment size of 25 Mb and 1 Mb 
in effective resolution (Gyapay et aL, 1996). 
The human 0AT2 was localized to chromosome 6 approximately 249.63cR 
from the top of chromosome linkage group, which is equivalent to 6p21.2 to 
p21.1 with reference that IcRgooo of X-ray breakage representing 270kb in DNA 
distance. Another two members, hOATl and hOAT3, both were mapped to 
l l q l l . 7 (Race et al., 1999). From this apparent result, a closer association is 
found between hOATl and hOAT3 than either of those with hOAT2. Moreover, 
the hOAT2 gene is located distal to haemochromatosis (HFE) gene at the position 
6p23 (Feder et al., 1996) and is proximal to acidic epididymal glycoprotein-like 
1 (AEGLl) gene (Hayashi et al., 1996) and peroxisome proliferative activated 
receptor, delta (PPARD) gene (Schmidt et aL, 1992) which are placed at the same 
location 6p21.2 - p21.1. The rapid increases in discovery of gene locations by 
latest advances of mapping technique such as fluorescence in situ hybridization 
and radiation hybrid mapping have given us an insight on some disease related 
genes. Although in most cases, diseases could be multifactorial and seldom 
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induced directly by expression or suppression of a single gene, at least some 
mutational hot-spots or some active translocation sites could be deduced by 
gathering information from the gene locations. 
4.6 Possible functions of hOAT2 
4,6.1 Hepato-renal relation 
Liver is a vital organ in maintaining the clearance and metabolism of 
endogenous and xenobiotics substances. Bile acid or bile salts synthesized from 
the liver are major constituents of bile and involve actively in the enterohepatic 
circulation. For example, Ntcp and Oatp are the two major bile salt transport 
systems locating at the basolateral membrane for the hepatic extraction of bile 
salts from portal blood plasma into bile (Hagenbuch et al., 1991; Jacquemin et aL, 
1994). In the other side, functional tests on organic anion transporters in kidney 
have being widely studied. Different endogenous and exogenous organic anions 
including metabolites and drugs have been examined to gather information about 
the transport of these compounds as well as their nephrotoxicities, p-
Aminohippurate (PAH) is one of the indicator which has long been used for the 
estimation of the renal plasma flow (Hirsch, 1976), and is known to be mediated 
by multispecific transporters such as OATl (Hosoyamada et aL, 1999; Sekine et 
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al, 1997) and 0AT3 (Kusuhara et cd., 1999; Race et al., 1999). It has been 
extensively used as a test substrate in analyzing transport efficacy of organic 
anion transporters in response to various drugs and endogenous substrate 
treatments. 
To date, even a number of organic anions transporters have been identified, 
it is not obvious how to deduce relationships between various organic anions or 
substrates carried by those particular transporters in either molecular structures or 
physiological properties. Salicylate, acetylsalicylate, PGE2, dicarboxylate and 
PAH are substrates for rat 0AT2 (Sekine et aL, 1998). However, other 
transporters could also mediate those organic anions, such as PAH transported by 
OATl and OATS (Sekine et al 1997). It is not hard to see in other kind of 
transporters like Oatpl, Oatp2, Oatp3 and Ntcp, they all have a common 
substrate, thyroxine (Kullak-Ublick, 1999). It seems that most organic anion 
transporters may specify a group of substrates, but overlapping of these anion 
groups might occur with even more than one kind of substrate involved. R0AT2 
is structurally similar to renal transporter rOATl as well as its substrate 
selectivity, however, the transport efficacy is different. As described, the PAH 
transport by rOAT2 occurred at a much lower level than that by rOATl (Sekine 
et al., 1997) but the mediation of salicylate by rOAT2 was much higher (Sekine 
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et al., 1998). To this point, it had been speculated that the tissue distribution of 
anions was different in the body, with evidence in previous finding showing that 
PAH is excreted mainly into the urine and rarely into the bile (Hirsch, 1976). 
Investigation on the hepatorenal relationship can provide us information on 
the transport mechanisms and the substrate specificity among the organic anion 
transporters. 
4,6,2 Substrate diversity 
Multispecificity is the common characteristic in the majority of organic 
anion transporters. In fact, these transporters are said to be multispecific rather 
than non-specific because they mediate many endogenous and exogenous 
compounds, but not any lipophilic or hydrophilic compounds. The four human 
OAT isoforms, hOATl, hOAT2, hOAT3 and hOAT4 have been shown to be 
expressed in kidney, though in different expression levels (Cha et al., 2000; 
Hosoyamada et aL, 1999; Race et al., 1999; Sekine et al。1998). To maintain the 
clearance of a wide variety of nephrotoxic compounds and metabolites from the 
body, the OAT family plays a key role in transporting these anions in kidney as 
well as in the metabolic center, liver. Moreover, such diverse substrate specificity 
property may serve another purpose. These multispecific organic anion 
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transporters have been deduced to own a characteristic substrate group, but it is 
believed there are still a number of substrates that have not been elucidated yet. 
Once the body has to deal with facing the attack of some kind of undefined toxic 
compounds that may generated exogenously or endogenously, these transporters 
could have the ability to deal with the toxin, followed by detoxification or 
excretion, and prevent accumulation in the body. 
It has been identified that some clinically important drugs are transported by 
or have inhibitory effect on the OATs. Uptake of drug such as methotrexate was 
found to be mediated by rOAT2 (Sekine et al., 1998); furosemide (a loop 
diuretic), probenecid (a uricosuric drug) and indomethacin (a nonsteroidal anti-
inflammatory drug) are regarded as inhibitors in hOATl-mediated PAH uptake 
(Hosoyamada et al., 1999). Furthermore, antiviral drugs like cidofovir and 
adefovir are novel substrates for both hOATl and rOATl, and accumulation of 
these drugs probably associated with nephrotoxicity (Cihlar et al., 1999). 
4.7 Fluorescence detection for subcellular localization 
Immimohistochemical studies on OATl proteins revealed that it is expressed 
exclusively on the basolateral membrane of S2 segments of proximal tubules in 
rat kidney, and none was found in the cytoplasmic vesicles (Tojo et al., 1999). 
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Accordingly, they suggested that organic anions might not be absorbed via an 
endocytotic pathway. Immunostaining using monoclonal antibody 2C5 detected 
rOAT2 on sinusoidal domains of hepatocytes but absence on the bile canalicular 
membrane (Simonson et al., 1994). Nevertheless, our fluorescence detection 
results showed the GFP tagged hOAT2 fusion proteins were localized evenly in 
the cytosolic area of mammalian cells, C2C12. The result was consistent when 
using hepatocarcinoma cell line, HepG2. Although hOAT2 is a putative 
transmembrane protein in regard to the preliminary analysis of its amino acid 
structure and hydropathicity, the transport mechanism or anions carrying 
pathway is still incompletely understood. Our results do not rule out the 
possibility that the GFP tag affected the localization of 0AT2 adversely, and 
further work needs to be done using GFP tagged to a C-terminus of the protein. 
4.8 Conclusion 
We have identified and characterized hOAT2 from the screening of human 
liver cDNA library. H0AT2 is believed to be the human homolog of rat 0AT2 
(NLT) since it shows 88% nucleotide sequence identity, and becomes the second 
member of multispecific organic anion transporter family. Primary structural 
analysis revealed that it possesses twelve putative transmembrane domains and a 
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large extracellular loop between transmembrane segment one and two, plus a 
possible A/-glycosylatoin site within the loop. 
RT-PCR on human adult tissues have demonstrated that hOAT2 has a high 
level of expression in liver and relatively weak expression in kidney, while 
expression was only observed in liver when analyzed on human fetal tissues. The 
expression pattern of adult human tissues is consistent with that of rat. 
Chromosomal localization of hOAT2 has been deduced to chromosome 6p21.2 -
> p21.1 using radiation hybrid mapping. 
The subcellular localization of hOAT2 was analyzed by using green 
fluorescence technique. It is surprising that hOAT2 was found to be localized in 
the cytoplasm, even in either liver or non-liver cell lines. Further studies are 
necessary to confirm this finding. 
Expression of hOAT2 was detected in liver cancer, though not quantitatively 
different from that of normal liver. We have raised an antibody against hOAT2. 
Western blotting using anti-hOAT2 antibodies deduced a band around 60 kDa on 
protein extract from Hep3B cells which is equivalent to the size of hOAT2 
protein. 
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4.9 Further aspects 
Up t i l l now, functional studies on hOAT2 are still at an initial stage. On the 
rat model, we know alpha-ketoglutarate and PAH are the substrates for rOAT2. 
In addition, hOAT2 was found to be expressed in liver cancer tissue. Transfection 
of hOAT2 into HepG2 cells could help us to investigate the transport efficacy of 
this transporter, and this strategy had been employed by Kullak-Ublick et al. in 
analyzing bile acid transport by Oatp (1996). The uses of radiolabelled substrates 
and antisense oligonucleotides from different regions are helpful in chasing the 
amount of the substrate uptake and determining the binding sequence of that 
protein respectively. Moreover, drugs and other substrates could be added to the 
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Fluorescent vector pEGFP C l 
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